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ABSTRACT 
LIM kinase 1 (LIMK1) is a unique dual specificity serine/threonine kinase containing 
two N-terminal LIM domains in tandem, a PDZ domain and a C-terminal catalytic domain.  
LIMK1 is involved in modulation of actin cytoskeleton through inactivating phosphorylation of 
the ADF (actin depolymerization factor) family protein cofilin. Recent studies have shown that 
LIMK1 is upregulated in breast and prostate cancer cells and tissues, promotes metastasis in 
animals and induces acquisition of an invasive phenotype when ectopically expressed in benign 
prostate epithelial (BPH) cells.  Furthermore, overexpression of LIMK1 was associated with 
altered sub cellular localization of the membrane type 1 matrix metalloprotease (MT1-MMP). 
Matrix metalloproteases (MMPs) are a family of zinc dependant proteolytic enzymes that 
hydrolyze extra cellular matrix and cell surface molecules. A number of MMPs including MMP-
2, MMP-9 and their activator MT1-MMP are over expressed in a variety of cancers including 
prostate cancer.  The abundant expression of these enzymes contributes to changes in the tumor 
microenvironment, which facilitate degradation of the surrounding collagen matrix and 
migration of cells through the matrix defects.  In this study, we show that MMPs are involved in 
LIMK1 induced invasion of otherwise non-invasive BPH cells.  We also show that (a) the kinase 
activity of LIMK is not essential for the invasive behavior of the cells and (b) the absence of 
LIM domains significantly retards cell invasion.  We have established transfected sub lines of 
BPH cells stably expressing 1) constitutively active LIMK1 (BPHLCA), 2) kinase dead LIMK1 
(BPHLKD) and 3) only the kinase domain of LIMK1 (BPHLK) for our study.  In vitro invasion 
assays revealed that LIMK1 induced invasion was inhibited by the MMP specific inhibitor, 
GM6001, and that cells expressing kinase-dead LIMK1 were equally invasive. Furthermore, 
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BPH cells expressing LIMK1 mutants expressed higher amounts of MMP-2 and MMP-9. 
Substrate zymography revealed increased concentration of secreted MMP-2 and MMP-9 in the 
media of BPHLCA and BPHLK cells respectively compared to BPHV (vector control) cells. 
Quantitative RT-PCR also showed a ~10 fold increase in the steady state concentration of MMP-
2 in BPHLCA cells compared to the control BPHLV cells. Expression of active LIMK1 stimulated 
cell-surface expression of MT1-MMP in BPHLCA cells as determined by flow cytometry. A 
modest increase in expression of MT1-MMP was noted in BPHLKD cells compared to BPHLK 
and BPHV cells.  Immunoflourescence analysis indicated differential localization of MT1-MMP 
and LIMK1 in BPH cells expressing different mutants of LIMK1.  Co-localization of LIMK1 
and MT1-MMP in the plasma membrane and in the perinuclear region was also evident in these 
cells.  Furthermore, here we provide evidence that suggests a functional role for phosphorylated 
(activated) LIMK1/2 (p-LIMK1/2) during mitosis through its association with γ-tubulin. 
Immunoflourescence analysis showed distinct co-localization of γ -tubulin and p-LIMK1/2 in the 
centrosomes during mitosis from early prophase to the beginning of telophase.  No association 
was seen in the interphase or in late telophase. Phospho-LIMK1/2 was co-precipitated in 
immunoprecipitates of γ -tubulin using an anti- γ -tubulin antibody suggesting a physical 
association between these proteins in a complex. This finding reveals a novel role of LIMK1 in 
the mitotic process.   
In summary, our data suggests that MMPs are involved in LIMK1 induced invasion of 
prostate epithelial cells, and that this effect is mediated through altered expression and activation 
of specific MMPs.  Furthermore, LIMK1 induced invasion is dependant on the presence of LIM 
domains more than the kinase activity.  Finally, we show that phosphorylated LIMK1 and 
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LIMK2 are involved in the mitotic process in a stage specific manner through its association 
with the centrosomal protein γ -tubulin. Because LIMK1 promotes invasion in vitro, regulates 
expression of MMPs, and is involved in mitotic processes, it is an attractive drug target for 
prostate cancer therapy. 
 
 v
 
 
 
 
 
 
 
 
Dedicated to my family and friends. 
Your support, confidence and love carried me. 
 vi
ACKNOWLEDGMENTS 
I would like to thank my creator for allowing me the privilege and opportunity to obtain 
higher education.  I thank Dr. Ratna Chakrabarti, for giving me the opportunity to conduct 
research in her lab.  Her commitment to training students, dedication to biomedical research and 
high standards has guided me throughout my graduate career.  I would also like to thank my 
committee members, Dr. Karl Chai, Dr. Debopam Chakrabarti and Dr. Cristina Fernandez-Valle, 
for their assistance in completion of my thesis and encouragement.  Special thanks go to my 
spouse Lex for his patience understanding.   
I would like to recognize Dr. Annette Khaled and Courtney Thaxton for assistance with 
flow cytometry and confocal imaging, respectively.  Sincere thanks goes to all my lab sisters and 
brothers, especially Raji, Brian, Mike, Lawrence and Chiro.  To my children Denekua and Judah, 
I thank you for providing me with unconditional love and motivation.  Finally I would like to 
thank my father and mother, you have made it possible, I love you both.   
 vii
TABLE OF CONTENTS 
LIST OF FIGURES ............................................................................................................ x 
LIST OF TABLES............................................................................................................ xii 
1. INTRODUCTION .......................................................................................................... 1 
1.1 Facts about Prostate Cancer ...................................................................................................1 
1.2 Stages of the Disease .............................................................................................................1 
1.3 Treatments..............................................................................................................................4 
1.4 Molecular Biology of Prostate Cancer...................................................................................5 
1.4.1 Cell Cycle Regulation in Prostate Cancer...................................................................... 6 
1.4.2 Growth Factors Common to Prostate Cancer ................................................................ 6 
1.4.3 Malfunctioning Genes in Prostate Tumors .................................................................... 7 
1.4.4 Role of Androgen........................................................................................................... 9 
1.4.5 Roles of Actin Cytoskeleton and Microtubules ........................................................... 10 
1.5 Angiogenesis and Metastasis ...............................................................................................11 
1.5.1 Matrix Metalloproteinases ........................................................................................... 12 
1.5.2 Membrane Type I Matrix Metalloproteinase............................................................... 15 
1.5.3 Matrix Meatlloproteinase-2/9 ...................................................................................... 17 
1.6 LIM Kinase 1 .......................................................................................................................18 
1.6.2 Role of LIMK 1 in Cancer Progression ....................................................................... 21 
1.6.3 LIMK1 in Cell Cycle Regulation................................................................................. 24 
1.7 Research Done in this Laboratory........................................................................................26 
1.8 Aims of Research.................................................................................................................26 
 viii
2: MATERIALS AND METHODS.................................................................................. 28 
2.1 Cell Culture..........................................................................................................................28 
2.2 Preparation of LIMK1 Constructs .......................................................................................30 
2.2.1 Generation of LIMK1 Mutants .................................................................................... 34 
2.3 Generation of Stable Cell Lines...........................................................................................34 
2.4 RNA Extraction ...................................................................................................................37 
2.5 Reverse Transription PCR ...................................................................................................38 
2.6 Preparation of Crude Protein Extracts .................................................................................38 
2.7 Western Blot Analysis .........................................................................................................41 
2.8 In vitro Invasion Assay ........................................................................................................41 
2.9 Gelatin Zymography ............................................................................................................43 
2.10 Quantitative Real-Time PCR .............................................................................................44 
2.11 Flow Cytometry .................................................................................................................45 
2.12 Dual label Immunofluorescence Analysis .........................................................................48 
2.13 Preparation of Nuclear and Cytoplasmic Extracts .............................................................50 
2.14 Immunoprecipitation..........................................................................................................50 
2.14.1 Calf Intestinal Alkaline Phosphatase Treatment........................................................ 51 
3. RESULTS ..................................................................................................................... 52 
3.1 Expression Analysis of LIM kinase 1 Transgene in Transfected BPH cells .......................52 
3.2 Catalytically Inactive LIMK1 is Invasive............................................................................57 
3.3 LIMK 1 Induced Invasion is Mediated by Matrix metalloproteinases ................................60 
 ix
3.3.1 LIMK1 Expression Altered the Concentration of Secreted pro-MMP2 and pro-MMP9 
and increased mRNA Concentration of MMP2.................................................................... 63 
3.4 MT1-MMP Expression positively Correlates with the Concentration of active LIMK1 ....67 
3.5 Phospho-LIMK1/2 Associates with γ-Tubulin ....................................................................74 
4. DISCUSSION............................................................................................................... 79 
4.1 LIM kinase 1 and Matrix metalloproteases .........................................................................79 
4.2 LIM KINASE 1 and γ-Tubulin ............................................................................................84 
LIST OF REFERENCES.................................................................................................. 86 
 
 x
LIST OF FIGURES 
Figure 1 Prostate Cancer Distribution............................................................................................. 2 
Figure 2 Anatomy of the Prostate ................................................................................................... 3 
Figure 3 Stages in the Development of a Tumor.  Outline of the process of tumor initiation and 
acquisition of metatastasis ............................................................................................................ 13 
Figure 4 Stucture of Matrix metalloproteinases............................................................................ 14 
Figure 5 Activation mechanisms of MMPs .................................................................................. 16 
Figure 6 Structure of LIMK1........................................................................................................ 19 
Figure 7 Activation and function of LIMK1................................................................................. 22 
Figure 8 Gamma tubulin co-localizes with phospho-LIMK1 to the centrosome during mitosis . 25 
Figure 9 LIMK1 coding sequence ................................................................................................ 31 
Figure 10 LIMK1 ORF amino acid sequence............................................................................... 33 
Figure 11 LIMK1 Constructs........................................................................................................ 35 
Figure 12 Electrophoresis analysis of total RNA showing intact ribosomal RNA....................... 53 
Figure 13 Reverse transcription PCR ........................................................................................... 53 
Figure 14  Flag expression confirms integration of LIMK1 mutants in BPH cell chromosome.. 55 
Figure 15 Expression analysis of LIMK1.  BPH cells transfected with LIMK1 mutants ............ 56 
Figure 16 Invitro Invasion assays of EGF treated transfected BPH cells..................................... 58 
Figure 17 Percent of invasion of BPH-LIMK1 cell lines ............................................................. 59 
Figure 18  Inhibition of MMPs decreased invasion of BPH cell lines ......................................... 61 
Figure 19  MMP inhibitor GM6001 reduced the invasiveness of BPH cells expressing LIMK1 62 
Figure 20 Gelatin zymography of the secreted Matrix Metalloproteinase 2 ................................ 64 
 xi
Figure 21 Gelatin zymography of secreted Matrix metalloproteinase 9....................................... 65 
Figure 22 Quantitative Real-time PCR analysis of MMP-2 steady state mRNA......................... 66 
Figure 23  Flow cytometric analysis of MMP-14 cell surface expression in transfected BPH cell 
lines. .............................................................................................................................................. 68 
Figure 24 Relative Expression of MT1-MMP in BPH cells expressing different domains of 
LIMK1. ......................................................................................................................................... 69 
Figure 25 Expression of Pro-MT1-MMP and active MT1-MMP in BPH-LIMK cell lines......... 71 
Figure 26 MT1-MMP localization studies of BPH cells expressing mutant LIMK1................... 73 
Figure 27  Titration of phospho-LIMK1/2 antibody in BPHL cells............................................. 75 
Figure 28 Biochemical interactions between phospho-LIMK1 and γ-tubulin.............................. 77 
 
 xii
LIST OF TABLES 
Table 1 Composition of buffers used............................................................................................ 29 
Table 2 Primers used for generate LIMK1-3XFLAG fusion protein ........................................... 32 
Table 3 Primers used for generation of LIMK1 mutants.............................................................. 36 
Table 4 PCR Conditions for LIMK1 Mutagenesis ....................................................................... 36 
Table 5 Primers used in RT-PCR.................................................................................................. 39 
Table 6  RT-PCR Amplification Summary .................................................................................. 40 
Table 7 Antibodies Used in Protein Detection ............................................................................. 42 
Table 8  Quantitative  PCR amplification summary..................................................................... 46 
Table 9  Primers used in Real Time PCR ..................................................................................... 47 
 
 1
1. INTRODUCTION 
1.1 Facts about Prostate Cancer 
Prostate cancer is the second most deadly cancer in men after lung cancer in the United States 
and the sixth leading cause of death of men overall [Ward-Smith, 2006] .  In fact, one in every 
six men will be diagnosed with the disease at some point in their life (Figure 1).  Prevalence rates 
of prostate cancer remain significantly higher in African Americans compared to white men and 
Hispanics [Theodorescu and Pollack, 2003].  Furthermore, mortality rates for African Americans 
are at least doubled compared to men of other racial and ethnic groups.  In addition, family 
history is one of the strongest risk factors for prostate cancer [Paiss et al., 2006].  The 5-year 
relative prostate cancer survival rate for men with localized prostate cancer is 100%; however 
men with advanced stage of the disease have only a 33% chance of survival.  Prostate cancer is 
mainly diagnosed in men over age 65, nonetheless younger populations are also susceptible to 
the disease.  It affects all racial/ethnic groups and is a major health concern.   
1.2 Stages of the Disease 
The prostate rests in the pelvis (Figure 2) and is made up of branching glands with ducts that are 
lined with secretory epithelial cells and basal cells [McNeal, 1988].  Prostate cancer is a disease 
in which the epithelial cells that line the prostate gland mutate and begin to proliferate without 
regulation.  It is divided into six stages [Savage et al., 1997].  Stage 1 (T1) cancer is localized 
only in the prostate.  Stage 2 (T2) cancer is still localized in the prostate gland, but is larger in 
size. Stage 3 (T3) cancer is no longer confined to the prostate gland, but is larger in size. 
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Figure 1 Prostate Cancer Distribution 
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Figure 2 Anatomy of the Prostate  
The prostate gland is located below the bladder and surrounds the upper portion of the urethra. 
Oregon Health and Science University health center. medicalcenter.osu.edu/ 
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Stage 3 (T3) cancer is no longer confined to the prostate but has spread to nearby seminal 
vesicles.  Stage 4 (T4) cancer is detected in tissues far from the prostate, including lymph nodes 
(Stage N+) or even bone (Stage M+).  Symptoms when present, may include, frequent and 
painful urination, blood or semen in urine, erectile dysfunction and pain or stiffness in lower 
back, hips or thighs. There are several tests available for the screening and diagnosis of prostate 
cancer; these include PSA test, digital rectal exam, MRI scan, ultrasound, CT scan and biopsy.  
Of these, PSA test combined with digital rectal exam are routinely performed.  The PSA test 
measures the concentration of PSA (prostate specific antigen) in blood; which increases in men 
who have prostate cancer.  In the digital rectal exam, the physician indirectly assesses the 
prostate tissue for irregularity and roughness.   It is recommended that men over age 50 have 
PSA test and DRE done yearly [Rinnab et al., 2005]. 
1.3 Treatments 
The treatment options for prostate cancer are dictated by the stage of the cancer.  In some cases 
of “early staged” cancer, treatment is withheld until symptoms appear or change.  Treatments for 
stage 1 and 2 prostate cancer include radiation therapy, cryotherapy, prostatectomy and 
transurethral resection of the prostate (TURP).  The goal of these treatments is to destroy cancer 
cells before they spread to the rest of the body.  Hormone therapy (also called anti-androgen 
treatment) is the treatment option of choice for stage 3, stage 4 and stage N+ prostate cancer.  
This option is effective in slowing the rate of cancer growth by inhibiting hormones necessary 
for growth, development, differentiation and function of the prostate [Abrahamsson, 1999].  
Decursin has been recently identified as a novel therapeutic agent having potent anti-androgen 
activities [Guo et al., 2007].  Hormonal therapy also slows the spreading of cancerous cells to 
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other parts of the body.  In the most severe form of prostate cancer, M+, where cancerous cells 
become hormone resistant, there is currently no cure.  Nonetheless, administration of 
chemotherapeutic agents such as docetaxel combined with a bisphosphonate can be effective in 
extending life and reducing pain [Westendorf and Hoeppner, 2007]. However, these powerful 
toxic drugs eliminate both cancer cells and healthy cells. Herein lies one of the major issues that 
challenges prostate cancer treatment; the absence of reliable markers [Pu et al., 2005].  Thus, the 
need to identify molecular targets specifically involved in the growth and spread of cancer cells 
is urgent. 
1.4 Molecular Biology of Prostate Cancer 
Cancer is a group of more than 200 diseases, thus the causes of cancer are complex and in many 
cases unknown.  The disease is initiated by mutations caused by carcinogenic agents that exert 
their effect by either direct interaction with DNA or by indirect epigenetic events that modulate 
gene expression without directly reacting with the base sequence of DNA  [Ruddon, 1995].  
Carcinogenic agents are generally classified as either chemical, biological, genetic, or radiation 
[Pitot and Dragan, 1991].  They modify DNA sequences that code for proteins that either 
increases the malignancy of a tumor cell or increases the chance that a normal cell develops into 
a tumor cell [Osborne et al., 2004].  These mutated DNA sequences termed oncogenes, may 
manifest as transcription factors, growth factors, regulatory GTPases, cytoplasmic 
serine/threonine kinases, or cytoplasmic tyrosine kinases [Robert G. McKinnell, 2006].  In 
contrast, tumor suppressor genes code for proteins that have a repressive effect on regulation of 
the cell cycle or promote apoptosis.   
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1.4.1 Cell Cycle Regulation in Prostate Cancer 
Cancerous cells are capable of going through unlimited number of cell divisions without any 
signs of senesence. In mammalian cells, cell cycle progression is tightly regulated through the 
activity of cyclin dependant kinases (CDKs) [Sherr, 1996].  CDKs are stage specific kinases that 
allow transition of cells from one stage to the next.  Alteration of the activity and expression 
level of CDKs results in proliferation of cancer cells [Hashimoto et al., 2006].  The cell cycle is 
also controlled by checkpoints that detect errors in DNA replication and chromosome 
segregation.   Concomittant with excess cell proliferation, cancerous cells lose sensitivity to 
signals for adherence, differentiation or death [Collins et al., 1997].  Cyclin D1 and its binding 
partners (CDK4 and CDK6) are important regulators of G1 to S phase progression.  In prostate 
cancer, Cyclin D1 positively influences tumor growth by aberrant regulation of  androgen 
receptor [Burd et al., 2006].  Similarly, Cdc6, a cell cycle regulatory gene involved in formation 
of pre-replication complex is down regulated in prostate cancer [Robles et al., 2002].   
1.4.2 Growth Factors Common to Prostate Cancer 
The ability of cancer cells to promote cell proliferation, inhibit apoptosis and induce 
angiogenesis is a reflection of the upregulation of certain oncogenic signaling pathways 
[McCarty, 2004].  Biochemically, misregulation of growth factors and their respective signaling 
pathways is associated with prostate cancer progression [Reynolds and Kyprianou, 2006].  
Specifically,EGF/EGFR signaling pathway is over active in advanced prostate cancer [Culig et 
al., 1994].  Inhibition of EGFR tyrosine kinase casused apoptotic death of metastatic prostate 
cancer cell lines LNCap, DU145, and PC3 [Mimeault et al., 2007a].  EGF treatment also 
increased androgen dependant AR transactivation in the recurrent prostate cancer cell line CWR-
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RI [Gregory et al., 2004].  Administration of the antiandrogen bicalutamide combined with the 
antiestrogen tamoxifen reduces the synthesis of IGF-I in prostate cancer cells [Boccardo et al., 
2006].  In addition, recent studies showed that in DU145 prostate cancer cells, IGF-I induced 
EGFR transactivation leading to mitogenic activity [Zhou et al., 2006].  TGF-β suppresses 
growth in normal cells, however in aggressive tumor cells it actively participates in angiogenesis 
and extracellular matrix deposition [Pinkas and Teicher, 2006].    
1.4.3 Malfunctioning Genes in Prostate Tumors 
Tumor Suppressor Genes 
The p53 protein is the most commonly mutated tumor suppressor gene associated with human 
cancers [Harvey Lodish, 2000].  In normal cells, p53 causes arrest in G1/G2 phase in response to 
DNA damaged caused by γ-irradiation.  Cells lacking functional p53 are allowed to continue 
cycling in the presence of damaged DNA.  Mutations in p53 mainly occur in late stage prostate 
cancer in association with androgen independence and metastasis, but also occur in 
approximately 30% of early prostate cancer [SD Downing MSc, 2000].  Furthermore, restoration 
of wild type p53 by electroporation into PC3 cell xenografts markedly suppressed tumor growth 
compared to xenografts transfected with mutant p53 [Mikata et al., 2002].  
PTEN, was the first phosphatase identified as a tumor suppressor gene. It has the ability 
to remove phosphate groups attached to serine, threonine and tyrosine residues.  In prostate 
cancer, PTEN is inactivated by a combination of mechanisms including hemizygous deletion, 
homozygous deletion, point mutations and promoter methylation [Isaacs and Kainu, 2001].  Wu 
et al demonstrated that in prostate cancer cells with inactivated PTEN, the 
AKT/phosphoinositide-3 kinase pathway was constitutively activated due to increased 
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accumulation of PTEN substrate PIP3 [Wu et al., 1998].  Activation of this pathway resulted in 
suppression of apoptosis and increased cell survival.  Mutations in PTEN are usually seen in 
advanced prostate cancer and may play a role in acquisition of metastatic potential.   
Oncogenes 
Proto-oncogenes are normal genes that regulate cell growth and differentiation and become 
tumor inducing upon activation.  Activation can be accomplished by mutations that cause a 
change in protein structure resulting in increased protein activity or concentration. In prostate 
cancer, the c-myc oncogene has an important role in regulation of cellular proliferation, 
differentiation and apoptosis [Grandori et al., 2000].  Overexpression and amplification of c-myc 
gene is more prevalent in recurrent tumors and  metastatic lesions than primary tumors [Buttyan 
et al., 1987].  Recent studies demonstrated that down regulation of the c-myc gene resulted in 
growth inhibition and apoptosis in prostate cancer cell lines [Napoli et al., 2006].   
The Rho GTPases belong to the Ras superfamily of small GTP binding proteins that act 
as molecular switches involved in cell motility and invasion, cytoskeleton organization and 
signal transduction [Yao et al., 2006].  RhoC GTPase is over expressed in aggressive cancers and 
is required for prostate cancer cell invasion [Gioeli, 2005].    
The best characterized members of the Rho subfamily, RhoA, Rac1 and Cdc42 play 
important roles in cellular proliferation, transformation and cell cycle progression [Adnane et al., 
1998].  Ghosh et al have shown that RhoA participates in signaling pathways controlling prostate 
epithelial cell proliferation in a cell line derived from transgenic mice with prostate 
adenocarcinoma [Ghosh et al., 2002].  In addition, high levels of Rac1 activity has been shown to 
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suppress the expression of cyclin dependant kinase inhibitor p21 and promote uncontrolled cell 
growth in prostate cancer cell lines [Knight-Krajewski et al., 2004].   
Aurora kinases, another familiy of serine/threoninethat are involved in cell cycle 
progression from G2 phase to mitosis.  Aurora kinase A is involved in coordination of 
microtubule organizing center and Aurora kinase B functions in attachment of mitotic spindle to 
the centromere.  All three members (Aurora-A/B/C) of this gene family were reported to be over 
expressed in many human cancers [Katayama et al., 2003].   Deregulation of Aurora kinase A/B 
induces aberrant mitosis leading to chromosomal instability and centrosomal irregularity [Lee et 
al., 2006].  Absence of regulated cell division eventually induces anueploidy, which is a driving 
force in malignant progression [Ewart-Toland et al., 2005].  Recent studies show that Aurora 
kinase B expression in prostate tumors positively correlates with increased Gleason score 
[Chieffi et al., 2006].  Over expression of Aurora kinase A is noted in most high grade prostatic 
intraepithelial neoplasia lesions [Buschhorn et al., 2005]   
1.4.4 Role of Androgen 
The growth, development, differentiation and maintenance of the prostate gland relies on the 
production of androgens, mainly in the form of testosterone [Lindzey et al., 1994].  Androgen 
secretion from leydig cells is stimulated by leutinizing hormone which is released in response to 
binding of gonadotropin releasing hormone to gonadotropes in the anterior pituitary [Grossmann 
et al., 2001].  Androgens exert their effect through binding to androgen receptor (AR).  AR is a 
member of the steroid receptor superfamily and contains an N-terminal transcription activation 
domain, a central DNA binding domain, and a C-terminal steroid binding domain [MacLean et 
al., 1997].  Once testosterone enters the cell, 5α-reductase converts it to dihydrotestosterone 
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which has an higher affinity for AR [Denmeade et al., 1996].  Upon ligand binding, AR becomes 
activated and binds promoter sequences (androgen response elements) that drive the transcription 
of androgen responsive genes.   
Initially, like the normal prostate, cancerous prostate relies on androgens for growth.  
Thus, blocking the action of androgens causes tumor regression.  However many tumors 
eventually begin to regrow independent of androgens.  [Bhuiyan et al., 2006].  There are several 
possible  mechanisms by which prostate cancer cells become androgen independent.  Mutations 
in AR may allow it to bind ligands non-specifically and thus activate AR [Koivisto et al., 1998].  
Similarly, mutations in hormone binding not only causes increased sensitivity to other hormones 
but also may cause AR to be responsive to antiandrogens [Akimoto, 1998].  In addition, 
androgen refractory prostate cancer cells may bypass AR signaling as a result of constitutive 
action of regulatory molecules downstream of AR [Bonkhoff, 1998].  Comprehensive 
understanding of the molecular mechanisms by which prostate cancer cells become androgen 
independent is necessary in order to develop effective therapies for advanced prostate cancer.    
1.4.5 Roles of Actin Cytoskeleton and Microtubules 
Cell migration is characterized by changes in the actin cytoskeleton and is a critical component 
of tumor cell invasion and metastasis.  Altered distribution and activity of microtubules also 
contribute to the cells’ ability to migrate and interact with neighboring cells.  Reorganization of 
the actin cytoskeleton is the primary mechanism for cell migration and is subject to microtubule 
dependant activities [Yamazaki et al., 2005]. Recent studies indicate that microtubule influence 
on actin cytoskeleton is mediated through substrate contact formation [Rodionov et al., 1993].  
Rho family of small GTPases (RhoA, Rac1,Cdc42) regulate the dynamics of actin cytoskeleton 
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associated with cell shape and behavior [Zhuge and Xu, 2001].  These GTP binding proteins are 
active when GTP bound and inactive when GDP bound.  This activation status is regulated by 
GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEF).  Rho 
activation induces assembly of stress fibers and focal adhesions, GTP bound Rac induces 
peripheral actin accumulation and membrane ruffling and Cdc42 induces filipodia [Edwards et 
al., 1999].  The highly invasive prostate cancer cell line PC3 display 3-fold higher expression of 
RhoA compared to minimally invasive PC3 cells [Hodge et al., 2003].  Activated Rac1 and 
Cdc42 facilitate pRb hyperphosphorylation which induces E2F responsive gene transcription 
thereby allowing entry in S phase [Gjoerup et al., 1998].  An increase in these actin remodeling 
events are characteristic of metastatic tumor cells in various types of cancer [Wittekind and Neid, 
2005]. More recent studies show that the presence of lamellipodia (membrane ruffling) 
positively correlates with cell motility and polarity in prostate cancer cell lines [Strock et al., 
2006].  In addition, EGFR signaling causes activation of Rac 1 and subsequent membrane 
ruffling and lamellipodia formation [Malliri et al., 1998].  LIMK1 is a downstream effector 
kinase of Rac1 and Cdc42 that is directly involved in actin reorganization.  Furthermore, 
increased activity of LIMK1 enhances cell spreading, cell migration and lamellipodia formation 
Misra et al., 2005].  
1.5 Angiogenesis and Metastasis 
Solid tumors eventually stimulate outgrowth of capillaries by which new blood vessels are 
formed; a process known as angiogenesis.  These blood vessels penetrate the tumor growth 
supplying nutrients and oxygen and removing waste products [Varner, 2006].  This process is 
actually initiated by release of growth factors by tumor cells that signal the surrounding normal 
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host tissue to make proteins that stimulate growth of new blood vessels [Montesano et al., 1993].  
This event marks the beginning of the transition of the tumor to a malignant state.  Tumor cells 
metastasize by invading blood vessels or lymphatic channels where they are free to seed out onto 
tissue surfaces and develop secondary tumors.  This is the most deadly aspect of cancer.  In this 
process a tumor cell has to detach from the primary tumor and from the extracellular matrix 
(ECM).  Many cell adhesion proteins such as E-cadherin are missing or compromised in tumor 
cells [Sato et al., 1999].  This helps the cell to escape adhesion to other cells and allows it to 
move more freely.  During metastasis, tumor cells degrade the basement membrane in order to 
disperse into the circulatory system [Yee and Shiu, 1986].  Penetration of the basement 
membrane is accomplished through the action of degradative enzymes that may be secreted by 
the tumor cells themselves.  The steps involved in initiation, angiogenesis and metastasis are 
illustrated in Figure 3. 
1.5.1 Matrix Metalloproteinases 
Matrix metalloproteinase’s are a family of at least 26 enzymes, 15 of which contain zinc in their 
active site [Visse and Nagase, 2003].  There are two classes of MMPs, secreted proteins and 
membrane bound proteins.  Soluble MMPs are secreted into the extracellular space upon 
activation.  Similarly, membrane bound MMPs become inserted into the plasma membrane when 
activated.  Nonetheless, most MMPs are characterized by a regulatory pro-domain, a catalytic 
domain, a linker region and a hemopoexin domain [Hideaki Nagase, 2004].(Figure 4).  MMPs 
are primarily involved in the turnover of the ECM.  They also have roles in embryonic 
development, tissue remodeling, wound healing and angiogenesis [Giambernardi et al., 1998].   
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Figure 3 Stages in the Development of a Tumor.  Outline of the process of tumor initiation and 
acquisition of metatastasis 
Nelson, et al., 2000 
 
 
 14
 
 
Figure 4 Stucture of Matrix metalloproteinases 
72kD Pro-MMP-2, 92kD, Pro-MMP-9, 66kD Pro-MT1-MMP.  Upon activation, the signal peptide and pro domain becomes cleaved 
exposing the active site of the enzyme.  Signal peptide (purple), propeptide/regulatory prodomain (gray), hemopoexin domain (red), 
fibronectin domain (blue).  Catalytic domains are represented by double arrows. 
Pro-MMP-2 propeptide  ZN2+ C-terminal domain Signal peptide 
Collagen like domain
Signal peptide propeptide  ZN
2+ C-terminal domainPro-MMP-9 
Signal peptide propeptide Zn2+ C-terminal domain Pro-MMP-14 Transmembrane Cytoplasmic domain 
Fibronectin type II 10-14 aa’s containing R-Q-K-R; furin recognition 
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Membrane-type MMPs are anchored to the membrane by a transmembrane domain or by GPI 
anchored proteins.  Activity of MMPs is regulated by a family of four endogenous inhibitors 
TIMP 1-4 [Blavier et al., 2006].  Extracellular matrix metalloproteinase inducer (EMMPRIN) 
plays a role in activation of MMPs and correlates with tumor progression [Ueda et al., 2007].  
This family of proteolytic enzymes are collectively capable of degrading all components of the 
ECM and are therefore major implicators of tumor cell invasion in a variety of cancers [Karadag 
et al., 2004]. 
1.5.2 Membrane Type I Matrix Metalloproteinase 
Membrane type 1 matrix metalloprotease also called MMP-14, is anchored to the plasma 
membrane through its transmembrane domain such that the catalytic domain is exposed on the 
surface of the cell [Nagakawa et al., 2000].  Activation of MMP-14 requires removal of the pro-
peptide by a member of the proprotein convertase family, furin, resulting in a 57kDa  active 
enzyme [Yana and Weiss, 2000].  Once cleaved, MMP-14 is inserted into the plasma membrane 
where TIMP-2 binds to its N terminus and it associates with a neighboring MMP-14 protein to 
activate matrix metalloproteinase 2.  Substrates for MMP-14 include, collagens I-III, fibronectin, 
laminin-1, vitronectin, dermatan sulfate proteoglycan, proMMP-2 and proMMP13.  The known 
steps of the activation mechanism of MT1-MMP are outlined in figure 5a.   
 
Expression of MT1-MMP is strongly associated with tumor progression and metastasis in almost 
all cancers [Hofmann et al., 2000]. Sounni et al showed that over expression of MT1-MMP 
promotes tumor growth and angiogenesis in breast cancer cells [Sounni et al., 2002].  Elevated 
levels of MT1-MMP were shown to facilitate tumor progression and increase the growth of  
 16
 
Figure 5 Activation mechanisms of MMPs 
A: Pro-MMP-2 and Pro-MT1-MMP activation mechanism.  Upon cleavage by furin convertases inside the cell, the 
pro-peptide regulatory domain of MT1-MMP is cleaved.  Next the MT1-MMP is inserted into the plasma membrane 
with the catalytic domain exposed to the extra cellular space.  Activation of pro-MMP-2 by MT1-MMP is assisted 
by binding to a TIMP-2/MT1-MMP complex, which presents pro-MMP-2 to an adjacent active MT1-MMP.   B: 
Activation of Pro-MMP-9.  Tissue inhibitor of matrix metalloprotease 1 (TIMP-1) binds to and inhibits pro-MMP-9.  
In the absence of TIMP-1, MMP-3 readily activates pro-MMP-9.  Formation of the ternary complex TIMP-1/MMP-
3/pro-MMP-9 causes the interaction between pro-MMP 9 and TIMP1 to be weakened.  ProMMP 9 partially 
dissociates from the complex and can be readily activated by free MMP-3. 
 
Furin like covertases 
Pro-MT1-
MT1-
Pro-MMP-
MMP-
Pro-MMP-
TIMP
MMP
MMP
Pro-
MMP
BA
TIMP
MMP
Pro-MMP-
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malignant melanoma in vivo[Iida et al., 2004].  With its catalytic domain exposed to the ECM 
environment, MT1-MMP is especially important in pericellular proteolysis.  In prostate cancer, 
MT1-MMP has been shown to correlate with tumor stage and promote metastasis of prostate 
cancer cells to the lymph node and lung [Cao et al., 2005].  MMP-14 degrades several 
components of the ECM; this degradative activity is enhanced by activation of latent MMP-2 and 
MMP-9.  Hence MT1-MMP is the most important proteinase involved in cancer cell migration, 
invasion, and metastasis.    
 
 
1.5.3 Matrix Meatlloproteinase-2/9 
Matrix metalloprotease-2 and matrix metalloprotease-9 also termed gelatinase A and gelatinase 
B respectively, are members of the matrixin family that are secreted into the extracellular space.  
Like most MMPs, gelatinases are characterized by a signal peptide, a propeptide, and a catalytic 
domain.  Gelatinases have an additional fibronectin type II domain and gelatinase B has a unique 
collagen like domain (Figure 4).  Gelatins, collagen IV and V, aggrecan, elastin, and vitronectin 
are substrates common to both gelatinases [Kherif et al., 1998].  Collagen I, VII, X, and XI, 
tenascin C and β-amyloid protein precursor are substrates unique to Gelatinase A.  Likewise, 
collagen XIV is an additional MMP-9 substrate.  However, recent studies have identified Ym1 
and S100 proteins as substrates for MMP-2, MMP-9 or both [Greenlee et al., 2006].  These novel 
substrates have key roles to play in the response to parasitic infections [Hung et al., 2002] and 
inflammation [Eue et al., 2002].  Although MMP-2 and MMP-9 have been implicated in tumor 
cell invasion in a variety of cancers, their role in prostate cancer is poorly defined.  Activation of 
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MMP-2 occurs at the plasma membrane and is mediated by MMP-14 and TIMP-2 [Hernandez-
Barrantes et al., 2000].  Active MMP-3 cleaves and activates proMMP-9, however a number of 
proteolytic enzymes are capable of activating MMP-9 in vitro [Ramos-DeSimone et al., 1999].  
The matrixin family of ECM degrading enzymes are capable of increasing their proteolytic effect 
by activating each other and substrate overlap.  The known steps of MMP-2, MMP-9 and MMP-
14 activation are depicted in (Figure 5b).   
Enhanced expression of MMPs has been correlated with increasing malignancy 
[Golubkov et al., 2005].  Nagakawa et al have shown that there is increased expression of MMP-
14 in androgen independent and invasive prostatic cancer cell lines [Nagakawa et al., 2000].  In 
addition, MMP2 expression has been shown to be involved in the process of prostate cancer 
invasion and metastasis [Liao et al., 2003].  Further, increased activity of MMP-9 in prostate 
cancer cells has been correlated with tumor cell metastasis [Wilson et al., 2004].  
1.6 LIM Kinase 1 
LIM kinases and testes specific protein kinase (TESK) are subfamilies of LISK kinases, each 
with two family members; LIMK1/2 and TESK1/2 respectively.  LISK kinases are 
morphogenesis kinases that stabilize the structure of actin cytoskeleton through phosphorylation 
and inactivation of cofilin [Manning et al., 2002].  LIMK1 is a dual specificity serine/threonine 
and tyrosine kinase that has two zinc finger motif LIM domains, a PDZ domain, and a kinase 
domain (Figure 6).  Within the PDZ domain there are two nuclear export signal and within the 
kinase domain there is a nuclear localization signal [Yang and Mizuno, 1999].  LIM kinases are 
predominantly expressed in the brain and neural tissue [Yang et al., 2004].  There is substantial  
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Figure 6 Structure of LIMK1 
LIMK1 contains four domains, two consecutive LIM domains, a PDZ domain and a kinase 
domain.  Within the PDZ doamain two nuclear export signals are present.  Within the kinase 
domain there is a nuclear localization signal. 
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evidence identifying LIMK1 gene deletion as a cause for development of cognitive disorder 
observed in patients with Williams Syndrome [Hoogenraad et al., 2004]. 
 
1.6.1 Regulation and Function of LIMK 1 
LIMK1 activity influences actin reorganization by regulating the activation status of actin 
depolymerization factor cofilin.  Upon phosphorylation by LIMK1, cofilin is unable to induce 
globular actin (G-actin) formation.  In eukaryotic cells, cofilin binds to filamentous actin (F-
actin) causing a conformational change in the actin subunits resulting in severing of F-actin to G-
actin.  Cofilin bound globular actin then associates with ADF-profilin, which causes cofilin/G-
actin dissociation and promotes actin polymerization [Moriyama et al., 1996].  This cycle of 
actin polymerization and depolymerization is continuous.  LIMK1 inactivates cofilin by 
phosphorylation on serine 3 residue [Toshima et al., 2001].  Thus inactive cofilin cannot sever 
actin polymers and there is an accumulation of filamentous actin in the cell.  Further, increased 
activity of LIMK1 causes actin remodeling events that may induce formation of lamellipodia, 
filipodia and stress fibers.  Activity of LIMK1 is regulated through the Rho subfamily of small 
GTPases [Lou et al., 2001].  Stimulation of EGF receptor signaling pathway has been shown to 
activate Rho GTPases [Nogami et al., 2003].  GTP bound Rac 1, a member of this subfamily, 
binds to PAK (p-21 activated kinase) homodimers at the N-terminus regulatory domain [Parrini 
et al., 2002].  Binding of Rac 1 or its family member Cdc42, causes release of PAK’s auto 
inhibitory domain from the kinase domain, resulting in cross phosphorylation and activation of 
PAK1/PAK4 which can, in turn, activate LIMK1[Stofega et al., 2004].  Activation of LIMK1 by 
Rac1 and Cdc42 mediated by PAK causes the formation of lamellipodia and filipodia 
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respectively.  Inactive LIMK1 is maintained in “closed” conformation with LIM domains 
associated with the kinase domain (Figure 7).  Upon phosphorylation at T508, LIM domains of 
LIMK1 dissociate from the C-terminal and the kinase domain is available for substrate 
phosphorylation. LIMK1 inactivates cofilin.  As a result cofilin is unable to bind to and induce 
severing of filamentous actin.  Panel C:  Dephosphorylation of cofilin by slingshot restores it’s 
activity.  Cofilin can then bind to F-actin causing dissociation of actin subunits and formation of 
G-actin.  Binding of ADF-profilin frees cofilin from G-actin. 
In its active conformation the N-terminus LIM domains of LIMK1 are accessible.  Active 
LIMK1 functions to inhibit the actin depolymerzing factor cofilin as mentioned above. LIMK1 
can also be activated by a third Rho subfamily member RhoA.  In this pathway, RhoA stimulates 
Rho-associated serine/threonine kinase (ROCK) which in turn phosphorylates and activates 
LIMK1 [Lin et al., 2003].  ROCK mediated activation of LIMK1 induces stress fiber formation.  
In addition, bone morphogenic protein type II receptor (BMPR-II) negatively regulates LIMK1 
through binding of the tail domain [Foletta et al., 2003].  The signaling mechanism underlying 
cytoskeletal changes directed by LIMK1 is depicted (Figure 7).  In addition, recent studies show 
that LIMK forms homodimer; an interaction promoted by Hsp90 resulting in 
transphosphorylation and increased stability [Li et al., 2006].    
1.6.2 Role of LIMK 1 in Cancer Progression 
In order for tumor cells to become metastatic they must detach from neighboring cells and 
degrade the extracellular matrix.  Both of these events require reorganization of the actin 
cytoskeleton.  Through the activity of LIMK1 there is reorganization of the actin cytoskeleton 
that coordinates the formation of lamellipodia and filipodia; structures which enhances cell 
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Figure 7 Activation and function of LIMK1  
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Panel A: GTP bound Cdc42 and Rac1 bind to PAK1 homodimers resulting in dissociation and 
transphosphorylation of PAK1.  Active PAK1 phosphorylates LIMK1 at T508, causing a 
conformational change in LIMK1 where kinase domain is available for substrate binding and 
LIM domains accessible for interacting partners.  Panel B:  Phosphorylation of cofilin at Ser3 by 
LIMK1 inactivates cofilin.  As a result cofilin is unable to bind to and induce severing of 
filamentous actin.  Panel C:  Dephosphorylation of cofilin by slingshot restores it’s activity.  
Cofilin can then bind to F-actin causing dissociation of actin subunits and formation of G-actin.  
Binding of ADF-profilin frees cofilin from G-actin. 
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migration by projecting the leading edge of the cell [Small et al., 1999].  Davila et al have shown 
that partial reduction in LIMK1 abolished invasiveness of the metastatic prostate cancer cell line 
PC3 [Davila et al., 2003].  In addition, ectopic expression of LIMK1 promoted acquisition of 
invasiveness in benign prostate epithelial cells.  Introduction of a dominant negative mutant of 
LIMK1 in breast cancer cells decreased motility and metastatic lesions in animals [Yoshioka et 
al., 2003].  In fact, LIMK1 has been implicated in breast tumor cell growth, angiogenesis and 
invasion [Bagheri-Yarmand et al., 2006].  Taken together, current findings implicate LIMK 1 as 
a putative oncogene in prostate cancer. 
1.6.3 LIMK1 in Cell Cycle Regulation 
LIMK1/2 regulate actin cytoskeletal reorganization through phosphorylation of cofilin.  Because 
actin reorganization is a key event in mitosis and cytokinesis, LIMK1 has been implicated in cell 
cycle progression.  Reduction of LIMK1 alters cell proliferation in prostate cancer cells by 
arresting cells in G2/M. In addition, during prometaphase and metaphase LIMK1 becomes 
hyperphosphorylated and then returns to basal level as cells enter telophase [Amano et al., 2002].  
This phenomenon is evident in both normal breast cells (HUMEC) and metastatic breast cancer 
cells (MDAMB231), Figure 8.  Sumi et al have also shown that LIMK1 activity is low during 
interphase and peaks during mitosis [Sumi et al., 2002].  Moreover LIMK1 has been shown to 
interact with 14-3-3ζ and p57Kip2, proteins involved in cell cycle check point control and 
regulation of CDKs, respectively [Yokoo et al., 2003], [Peng et al., 1997].   
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Figure 8 Gamma tubulin co-localizes with phospho-LIMK1 to the centrosome during mitosis 
Panel A: Metastatic breast cancer cells stained with p-LIMK1 (red, arrow) and γ-tubulin (green, arrow) showed co-
localization to centrosome (merged image).  Panel B: During interphase p-LIMK1 staining was abolished.  γ-tubulin 
remained localized to the centrosome (green, arrow).  Panel C: Co-localization of γ-tubulin and p-LIMK1 to the 
centrosome is also evident in normal breat epithelial cells (HUMEC). 
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1.7 Research Done in this Laboratory 
Studies from our laboratory showed that ectopic expression of LIM kinase 1 is required for 
prostate epithelial cell invasion. Over expression of LIMK1 was also observed in prostate tumors 
and prostate cancer cell lines.  Our previous works showed that reduced expression of LIMK1 
resulted in G2/M arrest in metastatic prostate cancer cell lines.  In addition, ectopic expression of  
LIMK1 promoted invasiveness in benign prostate epithelial cells.  Our studies also 
revealed that the level of phosphorylated cofilin remained unchanged upon reduction of LIMK1 
expression.  Immunofluorescence analysis showed localization of MT1-MMP to lamellipodia 
structures and perinuclear region of PC3 cells. 
However, antisense RNA mediated reduction of LIMK1 in these cells reduced the 
accumulation of MT1-MMP at the cell periphery.   
 
HYPOTHESIS: We speculate that LIMK1 induced invasion in prostate epithelial cells is 
possibly occurring independent of cofilin inactivation and may involve members of MMP family 
of ECM degrading enzymes.   
1.8 Aims of Research 
In this study, we attempted to elucidate the roles of LIM domains and the kinase domain of 
LIMK1 in the invasion process and determine whether matrix metalloproteinaese are involved in 
LIMK1 induced invasion of BPH cells.  We have also attempted to determine any possible 
association between LIMK1 and γ-tubulin as LIMK1 is localized to the centrosomes during early 
phases of mitosis (unpublished observation). 
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Experimental Design:  
Cloning of constitutively active LIMK1, kinase dead LIMK1 and only the kinase domain of 
LIMK1 in a mammalian expression vector 
Generation of stable cell lines and selection of clones that express maximum amounts of LIMK1 
by western blot analysis 
Invitro invasion assays of transfected cells expressing different domains of LIMK1  
Flow cytometric analysis to study the cell surface expression and activation of MT1-MMP in 
transfected sublines 
Gelatinase zymography was used to evaluate secretion of soluble MMP-2 and MMP-9 by 
transfected cell lines 
Invitro invasion assays utilizing inhibitors against MMPs to confirm their roles in LIMK1 
mediated invasion 
Immunoflourescence staining to visualize subcellular distribution of LIMK1 and it’s co-
localization with MT1-MMP 
Immunoprecipitation reactions with γ-tubulin were done in order to substantiate a role of LIMK1 
in mitotic processes   
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 2: MATERIALS AND METHODS 
2.1 Cell Culture 
Benign prostate hyperplasia (BPH) cells were used as the model cell line to study the function of 
LIMK1, as these cells express low levels of the LIMK1.  BPH cells are immortalized luminal 
epithelial cells originally obtained from a 68 year old male diagnosed with BPH [Hayward et al., 
1995].  BPH cells were maintained in high glucose containing DMEM (pH 7.1) (Invitrogen), 
supplemented with 10% heat inactivated fetal bovine serum 1% antibiotic/antimycotic and 1% 
glutamine at 37◦C humidified incubator with 5% CO2 and 95% air.  Routinely, cells were 
subcultured by trypsinization.  To detach the cells, the monolayer was washed with 1X PBS 
(Table 1), incubated with 5mL/100mm dish of 1X trypsin (Table 1) at room temperature for 5 
minutes.  Next, the trypsin was poured off and the dish was incubated at 37◦C for approximately 
10 minutes.  Detached cells were resuspended in complete medium and plated at 1:5 split.  
Counfluency is usually attained within 48 hours. 
The human caucasian breast cancer cells MDA-MB-231 were also maintained in high 
glucose containing DMEM (pH 7.1) (Gibco), supplemented with 10% non-heat inactivated 
serum, 1% antibiotic/antimycotic and 1% penicillin streptomycin.  To detach the cells, the 
monolayer was washed with 1X PBS (Table 1), incubated with 2mL/100mm dish of 1X trypsin 
(Table 1)at 37◦C for 2 minutes.  Detached cells were resuspended in complete medium and 
plated at 1:5 split.  Counfluency is usually attained within 48 hours.  Both BPH and MDA-MB-
231 cells were harvested by resuspending trypsinized 
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Table 1 Composition of buffers used 
Name of Buffer Application Composition 
Lysis Buffer Protein extraction 50mM Tris pH 8.0, 120mM NaCl, 2.5mM 
EDTA, PMSF, 1mM Na3Vo4, 1%NP-40, 
10ug/mL leupeptin/aprotinin, 50mM NaF, 
40mM β-glycerophosphate 
Transfer Buffer Western blot 192mM glycine, 25mM Tris base, 20% 
methanol 
Running Buffer SDS-PAGE 192mM glycine, 25mM Tris base, 0.1% SDS 
Blocking Buffer Western blot 5% milk, 137mM NaCl, 0.1% Tween, 20mM 
Tris pH 7.6 
Tris buffered saline Western blot 137mM NaCl, 20mM Tris pH 7.6 
Tris buffered saline-
tween 20 
Western blot 137mM NaCl, 0.1% Tween, 20mM Tris 
pH7.6 
4X sample buffer Western blot 250mM Tris pH 6.8, 8%SDS, 40% glycerol, 
20% β-mercaptoethanol 
4X non-reducing 
sample buffer 
Zymography 250mM Tris pH 6.8, 8%SDS, 40% glycerol,  
Renaturing Buffer Zymography 2.5% Triton X-100 in distilled water 
Developing Buffer Zymography 50mM Tris pH 7.8, 0.2M NaCl, 5mM CaCl, 
0.02% NP-40 
Staining Solution Zymography 0.5% w/v Coomasie blue R-250, 5% v/v 
methanol, 10% v/v acetic acid 
Destaining Solution Zymography 10% v/v methanol, 5% v/v acetic acid 
1X PBS Cell Culture 50mM NaPO4, 300mM NaCl, 10% glycerol 
1X Trypsin Cell Culture 50mM NaPO4, 300mM NaCl, 10% glycerol,, 
5mM imidazole 
10X MOPS buffer RNA Gel preparation 50mM NaPO4, 300mM NaCl, 10% glycerol, 
150mM imidazole 
Kinase Assay buffer Kinase Assay 50mM Hepes, 150mM NaCl, 5mM MgCl, 
10mM NaF, 1mM Na3VO4, 5mM MnCl 
RIPA buffer Immunoprecipitation 1% NP-40, 50mM Tris pH 7.5, 2mM EDTA, 
150mM NaCL 
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cells in 1XPBS and precipitating at 500xg at 4◦C for 10 minutes.  Cell pellets were washed with 
5mL of 1XPBS and centrifuged again at 500xg at 4◦C for 10 minutes.  Pellets were stored at -4◦C 
until used for protein extraction. 
2.2 Preparation of LIMK1 Constructs 
A DNA fragment containing full-length coding sequence of LIMK1 (Figure 9) originally cloned 
in pIND vector (Invitrogen) was used to amplify a 878bp fragment of LIMK1 ORF flanking the 
stop codon using primers shown in table 2.  The reverse primer was designed to obtain a mutated 
stop codon and a XbaI restriction site.  The PCR product was cloned in pGEM-T Easy vector 
(Promega).  In parallel, the 3X flag epitope of the p3XFLAG-CMV vector (Sigma E4901) was 
amplified using primers containing XbaI and ClaI sites and cloned in pGEM-T Easy vector.  
Next, LIMK1 fragment (878bp) was cloned in pGEMT Easy containing 3X Flag at the 3’ end.  
Cloning was done by digesting both plasmids with SSTI and Xba I.  Since SSTI restriction site is 
present in the multiple cloning site of pGEM-T Easy, the digested product was used as an insert 
for pGEM-T Easy plasmid containing 3X flag epitope.  DNA sequence of the LIMK1 fragment 
with mutated stop codon and 3X flag tag was confirmed by sequence analysis (this construct was 
already prepared in the lab).  Next, the LIMK1 fragment was sub-cloned into pIND vector 
containing the full length LIMK1 sequence replacing the original 878bp sequence.  This cloning 
generated full-length LIMK1 coding sequence with 3X flag tag at the 3’ end.  Full length LIMK1 
with 3X flag fusion protein (Figure 10) was subsequently cloned into Sal I and Cla I site in 
pRev-TRE mammalian expression vector driven by CMV promoter (Clontech).    
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Figure 9 LIMK1 coding sequence 
LIM1domain (pink), LIM2 domain (green), PDZ domain (yellow), Kinase domain (teal).  
Mutated stop codon (red) and extra bases (gray).  Flag sequence and Cla I site (dark yellow, 
turquiose).  Primer binding site for amplification of kinase domain only (*,****).  Primer 
binding site for kinase dead mutant amplification (**,****).  Primer binding site for 
constitutively active mutant (***,****). 
ATGAGGTTGA CGCTACTTTG TTGCACCTGG AGGGAAGAAC GTATGGGAGA GGAAGGAAGC GAGTTGCCCG   70 
TGTGTGCAAG CTGCGGCCAG AGGATCTATG ATGGCCAGTA CCTCCAGGCC CTGAACGCGG ACTGGCACGC  140 
AGACTGCTTC AGGTGTTGTG ACTGCAGTGC CTCCCTGTCG CACCAGTACT ATGAGAAGGA TGGGCAGCTC  210 
TTCTGCAAGA AGGACTACTG GGCCCGCTAT GGCGAGTCCT GCCATGGGTG CTCTGAGCAA ATCACCAAGG  280 
GACTGGTTAT GGTGGCTGGG GAGCTGAAGT ACCACCCCGA GTGTTTCATC TGCCTCACGT GTGGGACCTT  350 
TATCGGTGAC GGGGACACCT ACACGCTGGT GGAGCACTCC AAGCTGTACT GCGGGCACTG CTACTACCAG  420  
ACTGTGGTGA CCCCCGTCAT CGAGCAGATC CTGCCTGACT CCCCTGGCTC CCACCTGCCC CACACCGTCA  490 
CCCTGGTGTC CATCCCAGCC TCATCTCATG GCAAGCGTGG ACTTTCAGTC TCCATTGACC CCCCGCACGG  560 
CCCACCGGGC TGTGGCACCG AGCACTCACA CACCGTCCGC GTCCAGGGAG TGGATCCGGG CTGCATGAGC  630 
CCAGATGTGA AGAATTCCAT CCACGTCGGA GACCGGATCT TGGAAATCAA TGGCACGCCC ATCCGAAATG  700 
TGCCCCTGGA CGAGATTGAC CTGCTGATTC AGGAAACCAG CCGCCTGCTC CAGCTGACCC TCGAGCATGA  770 
CCCTCACGAT ACACTGGGCC ACGGGCTGGG GCCTGAGACC AGCCCCCTGA GCTCTCCGGC TTATACTCCC  840 
AGCGGGGAGG CGGGCAGCTC TGCCCGGCAG AAACCTGTCT TGAGGAGCTG CAGCATCGAC AGGTCTCCGG  910 
GCGCTGGCTC ACTGGGCTCC CCGGCCTCCC AGCGCAAGGA CCTGGGTCGC TCTGAGTCCC TCCGCGTAGT  980 
CTGCCGGCCA CACCGCATCT TCCGGCCGTC GGACCTCATC CACGGGGAGG TGCTGGGCAA GGGCTGCTTC 1050 
GGCCAGGCTA TCAAGGTGAC ACACCGTGAG ACAGGTGAGG TGATGGTGAT GAAGGAGCTG ATCCGGTTCG 1120 
ACGAGGAGAC CCAGAGGACG TTCCTCAAGG AGGTGAAGGT CATGCGATGC CTGGAACACC CCAACGTGCT 1190 
CAAGTTCATC GGGGTGCTCT ACAAGGACAA GAGGCTCAAC TTCATCACTG AGTACATCAA GGGCGGCACG 1260 
CTCCGGGGCA TCATCAAGAG CATGGACAGC CAGTACCCAT GGAGCCAGAG AGTGAGCTTT GCCAAGGACA 1330 
TCGCATCAGG GATGGCCTAC CTCCACTCCA TGAACATCAT CCACCGAGAC CTCAACTCCC ACAACTGCCT 1400 
GGTCCGCGAG AACAAGAATG TGGTGGTGGC TGACTTCGGG CTGGCGCGTC TCATGGTGGA CGAGAAGACT 1470 
CAGCCTGAGG GCCTGCGGAG CCTCAAGAAG CCAGACCGCA AGAAGCGCTA CACCGTGGTG GGCAACCCCT 1540 
ACTGGATGGC ACCTGAGATG ATCAACGGCC GCAGCTATGA TGAGAAGGTG GATGTGTTCT CCTTTGGGAT 1610 
CGTCCTGTGC GAGATCATCG GGCGGGTGAA CGCAGACCCT GACTACCTGC CCCGCACCAT GGACTTTGGC 1680 
CTCAACGTGC GAGGATTCCT GGACCGCTAC TGCCCCCCAA ACTGCCCCCC GAGCTTCTTC CCCATCACCG 1750 
TGCGCTGTTG CGATCTGGAC CCCGAGAAGA GGCCATCCTT TGTGAAGCTG GAACACTGGC TGGAGACCCT 1820 
CCGCATGCAC CTGGCCGGCC ACCTGCCACT GGGCCCACAG CTGGAGCAGC TGGACAGAGG TTTCTGGGAG 1890 
ACCTACCGGC GCGGCGAGAG CGGACTGCCT GCCCACCCTG AGGTCCCCGA CGCACTGCAG ATATCGGTAC 1960 
CAGTCGACTC TAGAGGATCC CGGGCTGACT ACAAAGACCA TGACGGTGAT TATAAAGATC ATGACATCGA 2030 
CTACAAGGAT GACGATGACA AGTAGTGAAT CGAT                                        2064 
* 
** 
*** 
**** 
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Table 2 Primers used for generate LIMK1-3XFLAG fusion protein 
A. PCR primers used for the generation of 878bp LIMK1 fragment with mutated stop codon.  B.  Primers used to amplify 3XFLAG 
epitope . 
Template Forward primer  Reverse primer 
LIMK1-pIND RC147 GCTATGATGAGAAGGTGGATGTGT RC258 CCTCTAGACTCGTCACTACTTGTC 
p3XFLAG-CMV RC257 CAGATATCCAGCGACTACAAAGAC RC258 CCTCTAGACTCGTCACTACTTGTC 
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Figure 10 LIMK1 ORF amino acid sequence 
Amino acid sequence of LIMK1 ORF.  Pink: LIM domain 1.  Yellow: LIM domain 2.  Blue: PDZ domain.  Red: Kinase domain. Black residues are linker 
sequences. To generate constitutively active LIMK1, T508 (green) was removed and two gluatmic acid residues inserted.  To generate kinase dead LIMK1 an 
aspartic acid residue (green) within the kinase domain was replaced with alanine.  Amino acid sequences for 3X Flag epitope are in bold (purple). 
 
MRLTLLCCTW REERMGEEGS ELPVCASCGQ RIYDGQYLQA LNADWHADCF RCCDCSASLS HQYYEKDGQL  70 
FCKKDYWARY GESCHGCSEQ ITKGLVMVAG ELKYHPECFI CLTCGTFIGD GDTYTLVEHS KLYCGHCYYQ 140 
TVVTPVIEQI LPDSPGSHLP HTVTLVSIPA SSHGKRGLSV SIDPPHGPPG CGTEHSHTVR VQGVDPGCMS 210 
PDVKNSIHVG DRILEINGTP IRNVPLDEID LLIQETSRLL QLTLEHDPHD TLGHGLGPET SPLSSPAYTP 280 
SGEAGSSARQ KPVLRSCSID RSPGAGSLGS PASQRKDLGR SESLRVVCRP HRIFRPSDLI HGEVLGKGCF 350
GQAIKVTHRE TGEVMVMKEL IRFDEETQRT FLKEVKVMRC LEHPNVLKFI GVLYKDKRLN FITEYIKGGT 420
LRGIIKSMDS QYPWSQRVSF AKDIASGMAY LHSMNIIHRD LNSHNCLVRE NKNVVVADFG LARLMVDEKT 490
QPEGLRSLKK PDRKKRYTVV GNPYWMAPEM INGRSYDEKV DVFSFGIVLC EIIGRVNADP DYLPRTMDFG 560 
LNVRGFLDRY CPPNCPPSFF PITVRCCDLD PEKRPSFVKL EHWLETLRMH LAGHLPLGPQ LEQLDRGFWE 630 
TYRRGESGLP AHPEVPDDYK DHDGDYKDHD GDYKDHDG                                    669
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2.2.1 Generation of LIMK1 Mutants 
Constitutively active LIMK1 (BPHLCA) and kinase dead (BPHLKD) constructs were generated 
using Strategene’s Quick Change Site Directed Mutagenesis kit (Figure 11).  Procedures were 
followed according to the manufacturers protocol.  Briefly, using wild type LIMK1 as a 
template, two mutagenic primers (Table 3) were used for amplification with PCR conditions 
mentioned in table 4.  The PCR product was digested with Dpn1 and used for transformed of 
XL1-Blue Super competent cells.  Antibiotic resistant colonies were picked and DNA extracted 
using the boiling mini prep method.  The construct containing the kinase domain only was 
generated by PCR amplification using primers flanking the kinase domain.  The forward primer 
was designed to introduce an initiation codon.  Then the amplified product was cloned into Sal I 
and Cla I sites in the pRev-TRE vector.  Cloning of the LIMK1 fragments were initially verified 
by restriction digestion.  Finally, DNA sequences of all constructs were confirmed by sequence 
analysis.  
2.3 Generation of Stable Cell Lines 
Plasmid DNA containing LIMK1 fragments or the empty vector DNA were purified 
using Qiagen spin mini prep DNA purification kit.The day before transfection BPH cells (5X105) 
were seeded into six well dishes in complete growth media.  Five to seven micrograms of cDNA 
were used for transfection using Lipofectamine Plus 2000. Next day, media were replaced with 
warm OptiMEM (800uL) and cells were incubated for two hours at 37◦C.  Plasmid DNA was 
warmed to room temperature and mixed with lipofectamine diluted in OptiMEM (100uL). 
Lipofectamine  (12uL) Invitrogen).    
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Figure 11 LIMK1 Constructs 
To generate constitutively active LIMK1, threonine 508 was removed and two gluatmic acid 
residues inserted.  To generate kinase dead LIMK1 an aspartic acid 460 was mutated to alanine. 
Both mutations are within the kinase domain of LIMK1. 
 
 
LIM1 PDZ KINASE LIM2 FLAG
LIM1 PDZ KINASE LIM2 FLAG
KINASE FLAG 
BPHLCA
BPHLKD
BPHLK 
T508EE
D460A
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Table 3 Primers used for generation of LIMK1 mutants 
Construct Forward primer Reverse primer 
K RC271 GTCGACATGCCTCACGATACACT RC269 ATCGATTCACTACTTGTCAT 
KD RC300 CATCATCCACCGAGCCCTCAACTCCCAC RC301 
GTGGGAGTTGAGGGCTCGGTGGATGATG 
CA RC294 
CAAGAAGCGCTACGAAGAGGTGGTCGGCAAC 
RC295 
GTTGCCCACCACCTCTTCGTAGCGCTTCTTG 
 
Table 4 PCR Conditions for LIMK1 Mutagenesis 
To achieve multiple amino acid insertions and deletions, 18 cycles of amplication was necessary.  
Cycles Temperature Time 
1 95◦C 30s 
95◦C 30s 
55◦C 1min 
18 
68◦C 2min 
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DNA mixed with OptiMEM (100uL) was added to the mixture and incubated at room 
temperature for 30 minutes.  Next the DNA mixture was added to BPH cells containing 800uL of 
OptiMEM.  Transfected cells were incubated at 37◦ in a humidified CO2 incubator for 3 hours.  
Next, one mL of complete growth media supplemented with 20% FBS was added to the cells and 
incubation continued for 24hrs.   
After 48-72hrs post transfection, cells were treated with hygrpmycin (8ul/ml-Invitrogen).  
Antibitic resistant cells were cloned by incubating them with trypsin soaked cloning disc for 7-10 
minutes at room temperature and transferring the disc into 24 well dish (1 disc/well).  Cells were 
maintained in complete growth media containing hygromycin and screened for transgene 
expression as described below. 
2.4 RNA Extraction 
Total RNA was extracted from transfected cells using Promega total RNA extraction kit. 
Approximately 1.5X106 cells were harvested and processed for RNA extraction according to the 
manufacturers protocol.  Briefly, cell pellets were homogenized in denaturing solution by 
vortexing vigourously.  Then phenol chloroform was added to the suspension and samples were 
incubated on ice for 15 minutes.  Samples were then centrifuged for 20 minutes at 10000xg at 
4◦C.  After centrifugation, the aqueous layer was recovered and an equal volume of isopropanol 
was added.  Samples were then incubated at -20◦C for 18 hours to precipitate the RNA.  The next 
day 1mL of ice cold 70% ethanol was added to the solution and then centrifuged at 10000xg for 
10 minutes at 4◦C.  The resulting pellet was air dried for approximately 20 minutes and then 
resuspended in nuclease free water.  Total RNA concentration of each sample was determined in 
a spectrophotometer at 260nm wavelength.  Integrity of the RNA samples were determined by 
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formaldehyde (3%) agarose gel (1%) electrophoresis in 1XMOPS buffer (Table 1).  RNA 
samples were prepared for analysis by adding 15uL of RNA sample loading buffer (Sigma 4268) 
to 5uL of RNA sample (5-7ug) and boiling as 65◦C for 15 minutes. 
2.5 Reverse Transription PCR 
Copy DNAs of the transgenes from LIMK1 expressing cell lines were amplified using stratagene 
one step RT-PCR kit, according to the manufacturers protocol.  Each reaction contained total 
RNA sample (1ug), RNase free water, RT-PCR buffer, primers (20uM, Table 5), and dNTPs 
(0.4mM each, provided with kit).  Then samples were denatured at 65 ◦C.for 15 minutes and then 
cooled to 37◦C for 3 minutes in thermocycler.  Next, reverse transcriptase and DNA polymerase 
were added to the reaction and samples were incubated for the specified time (Table 6) for 
reverse transcription.  
2.6 Preparation of Crude Protein Extracts 
Fresh or frozen cell pellets were resuspended in protein extraction buffer (Table 1) with 
inhibitors and then subjected to freezing and thawing for 6-7 cycles in a dry ice ethanol bath.  
First suspended cells were frozen for approximately 1 min, thawed at 37◦C, and then vortexed 
vigourously for 20-30 seconds.  To ensure complete lysis, lysates were observed under the 
microscope.  Then lysates were centrifuged at 500xg for 15 minutes at 4◦C.  The supernatants 
were transferred to clean microfuge tubes and protein concentrations were measured using 
Bradford assay (BioRad).  A standard curve was generated using BSA (New England Biolabs) to 
quantify the protein concentration.   
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Table 5 Primers used in RT-PCR 
Description of primers used in reverse transcriptase PCR.  Amplification using Flag specific primer (RC269) confirmed 
expression of LIMK1 transgene. 
LIMK1 ORF Forward Primer Reverse Primer 
Position 872, PDZ 
domain 
RC145, TGGACGAGATTGACCTGCTGATTC RC269, ATCGATTCACTACTTGTCAT 
Position 1247, 
kinase domain 
RC130, CAGGTGAGGTGATGGTGATGAAGG RC269, ATCGATTCACTACTTGTCAT 
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Table 6  RT-PCR Amplification Summary 
Description of PCR conditions used in reverse transcriptase PCR. 
Cycle Temperature Time 
95◦C 1min 1 
42◦ C 90min 
40 95◦ C 30s 
50◦ C 30s  
68◦ C 4min 
1 68◦ C 10min 
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2.7 Western Blot Analysis 
Fifty micrograms of total proteins in crude cell lysates were denatured in 1X sample buffer 
(Table 1), boiled for 5 mins and separated by SDS-PAGE.  Seperated proteins in the gels were 
transferred to a polvinylidene fluoride membrane (Pall Corporation) at room temperature for 
18hrs at 20v in transfer buffer (Table 1). Membranes were stained with India ink (1:1000) for 15 
minutes at room temperature to visualize lanes.  Next, membranes were incubated in blocking 
buffer (5% milk TBS-T) for 90 minutes at room temperature.  Proteins in the membrane were 
detected by reacting with specific primary and secondary antibodies (Table 7) diluted in blocking 
buffer (Table 1) for specified the time (Table 7).  Membranes were washed extensively in 
washing buffer (Table 1) and positive signals detected by chemiluminescence using a west femto 
chemiluminescence HRP substrate detection kit from Pierce.   
2.8 In vitro Invasion Assay 
Treatment of Cells Prior to Seeding 
To sensitize cells for treatment with epidermal growth factor, 60% confluent dishes were washed 
with 1XPBS (Table 1) and incubated with phenol red free DMEM complete media supplemented 
with *10% charcoal stripped fetal bovine serum (CSFBS) for 48 hours.  Then the monolayer was 
washed with 1XPBS and incubated with serum free phenol red free DMEM media for 24hrs.  
(2.5 grams of charcoal was combined with .25 grams of dextran and q.s. to 1L in 1M tris and 
stored at 4◦ o/n.  The next day, the charcoal was autoclaved and combined with serum(1:1) ratio 
and stirred for 1hr at 45◦.  To remove charcoal the serum was centrifuged ) 
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Table 7 Antibodies Used in Protein Detection 
Antibody Application Concentration Incubation 
Flag (Sigma) Western blot 1:2000 1hr @ RT 
Gapdh Western blot 1:500,000 1hr @RT 
LIMK1 (Transduction laboratories) Western blot 1:100 O/N @ 4 ◦C 
Gamma tubulin (Sigma) Western blot 1:5000 1hr @ RT 
p-LIMK 1 (Abcam) Western blot 1:75 O/N @ 4 ◦C 
p-LIMK 2 (Abcam) Western blot 1:100 O/N @ 4 ◦C 
Bcl-2 Immunoprecipitation 1ug/100ug lysate O/N @ 4 ◦C 
Gamma tubulin (Sigma) Immunoprecipitation 1ug/100ug lysate O/N @ 4 ◦C 
Flag (Sigma) Immunofluorescence 35ug/mL 1hr @ RT 
MT1-MMP (Neomarker) Immunofluorescence 1:250 1hr @ RT 
Anti-mouse (Jackson Immunologicals) Western blot 1:30,000 30 min @ RT
Anti-rabbit  (Jackson Immunologicals) Western blot 1:20,000 30 min @ RT
Cy 3 conjugated antimouse Immunofluorescence 1:200 30 min @ RT
Cy 5 conjugated antimouse Immunofluorescence 1:200 30 min @ RT
p-LIMK1 (Cell signaling) Immunofluorescence 1:50 1hr @ RT 
Alpha tubulin Immunofluorescence 1:2000 1hr @ RT 
Flag (Sigma) Immunoprecipitation 1ug/100ug lysate 4hrs @ 4 ◦C 
MT1-MMP (Chemicon) Flow cytometry 5ug/million cells 3hrs @ 4 ◦C 
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Invasion Assay 
For the invasion assay, ECM fluorometric kit (ECM 554) from Chemicon was used.  Experiment 
was carried out according to the manufacturers protocol with some modifications.  Cells were 
seeded at a density of 1.25X105 in serum free media in matrigel coated inserts that had been 
rehydrated for 30 minutes.  In addition, EGF was added to the cell suspension at a final 
concentration of 10ng/mL.  For inhibition studies, the matix metalloproteinase inhibitor GM6001 
was added at a final concentration of 25uM. EGF (100nM) was added to the lower chamber as 
the chemoattractant.  Cells were incubated at 37◦C in a CO2 incubator for 48hrs.  At the end of 
incubation, media was removed from each insert and discarded.  Inserts were transferred to clean 
wells (24 well dish) containing 225uL of cell detachment buffer (provided with the kit) and 
incubated at 37◦C in a CO2 incubator for 1 hour.  During this incubation, samples were gently 
rocked back and forth every 15 minutes to facilitate cell detachment.  Also, cells that had 
completely traversed the matrigel membrane to the bottom wells were counted.  Next, 75uL of 
lysis buffer/dye solution (provided with the kit) was added to each well and incubated at room 
temperature for 15 minutes.  Lysis buffer/dye solution with no cells was used as a blank.  After 
incubation, 200uL from each sample was transferred to a clean 96 well plate for fluorescence 
measurement in a Wallac Victor 2 at 480/520 excitation/emission settings.   
2.9 Gelatin Zymography 
Transfected cells (2.5X105) cells were seeded into six well dishes and incubated for 24hrs.  Next 
day, media was replaced with phenol red free DMEM supplemented with 10% charcoal stripped 
FBS and cells were incubated for at 37◦C in a CO2 incubator for 48hrs.  Cells were then serum 
starved for 24hr at 37◦C in a CO2 incubator.  Next, cells were treated with EGF at a final 
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concentration of 10ng/mL for 24hrs at 37◦C in a CO2 incubator.  After incubation, the 
conditioned media was harvested and centrifuged at 500xg for 5minutes at 4◦C.  Supernatant was 
transferred to a clean microfuge tube and stored at -20◦ C.  For analysis, 15uL of each sample 
was incubated with 5uL of non-reducing loading buffer (Table 1) at room temperature for 15-20 
minutes.  Samples were then separated on a 10% SDS gel co-polymerized with 1mg/mL gelatin.  
Gelatin was dissolved at 60◦C. for 20 minutes.  Gels were run at 125v until the dye front ran off 
the gel.  For better separation, gels were run for an additional 10 minutes.  Next, gels were 
incubated in renaturing buffer (Table 1) for 30 minutes.  Gels were washed twice and then 
incubated in developing buffer (Table 1) for 30 minutes.  At this point, the developing buffer was 
decanted, fresh developing buffer was added and gels were incubated at 37◦C for 24hrs.  Next 
day, gels were stained in staining buffer (Table 1) until they became uniformly blue.  To see 
gelatinoic bands, gels were destained (Table 1) as needed.  Once bands appeared, gels were 
immediately dried for 3hrs.  Bands were quantitated by densitometric analysis using Gene snap 
software.   
2.10 Quantitative Real-Time PCR 
Total RNA extracts were obtained as described in section 2.3.  For cDNA synthesis, BioRad 
iScript kit was used according to manufacturer’s protocol. Briefly, RNase free water and 5X 
reaction mix (provided with kit) were added to total RNA samples (1ug). Next, samples were 
denatured at 65◦C for 15min, cooled to 37◦ C for 3 minutes in a thermocycler.  Reverse 
transcription was carried out at 42◦C in thermocycler for 90min.  Real-time PCR was performed 
using a kit (Biorad SYBR green).  This kit provided a 2X reaction mix to which primers, 
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cNDA (6uL), and nuclease free water was added to a final volume of 25uL.A RT-PCR reaction 
without revers transcriptase was used as a control.  Primer sequences and PCR cycles are 
indicated in tables 8 and 9, respectively.  Reactions were carried out in BioRad iCycler 
thermocycler. 
Calculation of Gene Expression 
Quantification of the target gene was calculated using ∆Ct method and GAPDH as a reference 
gene.   
To calculate relative expression, the target gene expression was normalized for each sample: 
2(CT(GAPDH)-CT(target gene)= Expression  
Fold change expression was calculated as a ratio of expression of target gene in normal cell line 
to expression of target gene in test cell line: Normal expression= ∆Ct normal cells/∆Ct normal 
cells; Tumor expression=∆Ct tumor cells/ ∆Ct normal cells. 
 
2.11 Flow Cytometry 
Treatment of Cells Prior to Seeding 
To sensitize cells for treatment with epidermal growth factor, 60% confluent cells were 
incubated with phenol red free DMEM complete media supplemented with 10% charcoal 
stripped fetal bovine serum for 48 hours.  Next, cell monolayers were washed with 1XPBS 
(Table 1) and incubated with serum free and phenol red free DMEM complete media for 24hrs.  
At this point, EGF (10ng/mL) was added to each dish and cells were incubated for 24 hours. 
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Table 8  Quantitative  PCR amplification summary 
Data was collected after each cycle of amplification.   
Cycle Temperature Time 
1 95◦C 30s 
95◦C 30s 40 
56◦C 30s 
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Table 9  Primers used in Real Time PCR 
Description of target sequences amplified in quantitative PCR. 
 
Protein Length Forward primer Reverse primer 
GAPDH 85bp ATGGCCTTCCGTGTTCCTAC TGATGTCATCATACTTGGCAGG 
MT1-MMP 295bp GTCTCCTGCTCCCCCT CGAACATTGGCCTTGATCTCA 
MMP-2 501bp GCAAGTTTCCGTTCCGCTTCC CAGTACCAGTGTCAGTATCAGC 
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MT1-MMP Surface Staining 
EGF treated cells were harvested by incubating with 3ml/00mm dish of cell stripper (Cell Gro) 
for 15-20 minutes.  Two ml of PBS was added to each dish and cells were collected.  Five X 
10^5 cells were aliquoted into 5mL falcon tubes and centrifuged at 500xg for 10minutes.  Cells 
were resuspended in 1XPBS with 3%FBS containing MT1-MMP antibody (Chemicon) at a 
concentration of 5ug/million cells.  Cells were incubated at 4◦C with end over end rocking for 
three hours.  Next, cells were washed in PBS with 3% FBS and centrifuged at 500xg for 5 
minutes.  This step was repeated twice.  Samples were incubated with the secondary antibody 
conjugated with Alexa 488 (molecular probes) at a concentration of 1:800 for 30min at 4C◦ with 
end over end rocking.  Cells were washed next in 1XPBS with 3%FBS and centrifuged at 500xg 
twice and resuspended in the fixation buffer (2% paraformaldehyde in 1XPBS).  To prevent 
clumping, pluronic solution (Sigma) was added to the cell suspension at a concentration of 
100uL/mL.  Prior to use, fixation buffer was autoclaved and filter sterilized.  Samples were 
stored at 4◦C until acquisition in a flow cytometer (FACS Calibur/BD Biosciences).   
2.12 Dual label Immunofluorescence Analysis 
Preparation of Polylysine Coated coated Coverslips 
Coverslips were coated with 1% Poly-L-lysine diluted in sterile borate buffer (2mM EDTA, 
89mM Tris/boric acid).  First, coverslips (12mm diameter, Fisher) were sterilized in 85% ethanol 
and allowed to air dry.  Next, 200uL of 1Xpoly-L-lysine was added to each coverslip and 
incubated for 10mins at room temperature. Poly-L-lysine was removed at the end of inubation 
leaving behind a thin layer.  Coverslips were allowed to air dry for approximately 30 minutes. 
 
 49
Treatment of Cells Prior to Staining  
Typically, 2X104 cells were seeded on poly-L-lysine coated 12mm diameter coverslips (Fisher) 
in 24 well dishes and incubated overnight at 37◦C in a CO2 incubator.  The next day or once cells 
adhered, media was changed to phenol red free DMEM containing 10% charcoal stripped FBS 
and incubation continued for 48hrs at 37◦C in a CO2 incubator.  Next, cells were treated with 
serum free media and incubated for another 24hrs. After 24hrs, cells were treated with EGF 
(10ng/mL) in phenol red free DMEM media for 30 minutes at 37◦C in a CO2 incubator.   
Immunostaining 
Cells were washed in 0.1M phosphate buffer (3X), and fixed in freshly prepared 4% 
paraformaldehyde in 0.1M phosphate buffer for 10mins.  Cells were washed in 0.1M phosphate 
buffer (3X) and permeabilized by incubating in 0.2% triton X100 for 10 minutes at room 
temperature.  Next, cells were washed with 0.2% tritonX100 in 0.1M phosphate buffer.  At this 
point, coverslips were removed from the culture dish and placed cell side up onto filter paper 
covered with parafilm.  Cells were subjected to blocking at room temperature in 10% goat 
serum, 0.2% triton X100 in 0.1M phosphate buffer for 1.5 hour.  Primary and secondary 
antibodies (Table 7) were diluted in blocking buffer and applied (75uL) to coverslips.  Primary 
antibodies were combined and applied to coverslips for 1hr.  Secondary antibodies were 
centrifuged at 12000xg for 3 minutes prior to use.  Coverslips were washed extensively with 
0.1M phosphate buffer (six times for 5 minutes each).  Cells were postfixed for 5 minutes and 
then stained with phalloidin (Company 1:40) for 15 minutes at room temperature.  Coverslips 
were washed with 0.1M phosphate buffer (3X) and then mounted with biomedia gel mount 
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(BioMeda).  Mounted cells were stored in the dark for 18hrs.  Flourescent cells were visualized 
in a confocal microscope (Carl Ziess) at 60X oil objective.  Images were also deconvoluted.   
2.13 Preparation of Nuclear and Cytoplasmic Extracts 
Nuclear extracts of MDA-MB-231 and BPH-LIMK were prepared using NE-PER kit (Pierce).  
Briefly, ice cold cytoplasmic extraction reagent I was added to cell pellet and vortexed 
vigorously for 15 seconds and incubated on ice for 10 minutes.  Then cytoplasmic reagent II was 
added to each suspension, vortexed for 5 seconds and incubated on ice for 1 minute.  To collect 
cytoplasmic extracts, samples were centrifuged at 16000g for 5 minutes.  To obtain the nuclear 
fraction, nuclear extraction buffer was added to the remaining pellet, vortexed for 15seconds 
then incubated on ice for 10 minutes.  The cycle of 15 second vortex and 10 minutes on ice was 
repeated until 40 minutes elapsed.  Sample were then spun down at 16000g for 10 minutes.  
Protein concentrations were determined using Bradford assay (BioRad).  Reagent dye (BioRad) 
and BSA (New England Biolabs) were used in preparation of standards. 
2.14 Immunoprecipitation 
Cell lysates were prepared as described above in RIPA buffer (Table 1).  Protein concentrations 
were determined using Bradford assays.  Typically, 1ug antibody per 100ug of protein was 
incubated at 4◦C for 4 hours.  Next, 30uL of protein A/G sepahrose beads (Santa Cruz 
Biotechnology) was added to the tube and incubated for 18 hours at 4◦C with end over end 
rocking.  Next day, samples were centrifuged at 100xg for 2 minutes at 4◦C.  Supernatants were 
removed and saved for analysis.  Beads were washed three times 5 minutes each in 500uL of 
RIPA buffer and centrifuged at 200xg for 5 minutes.  To separate protein complexes and beads, 
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16uL of distilled water and 5uL of 4X sample buffer were added to the beads, boiled for 5 
minutes and separated by SDS-PAGE.  Immunoprecipitated proteins were detected by western 
blotting as described above.    
2.14.1 Calf Intestinal Alkaline Phosphatase Treatment 
Nuclear extracts (500ug) resuspended in modified RIPA buffer (1%nonidet P-40, 50mM Tris pH 
8.5, 2mM EDTA, 150mM NaCL) were dephosphorylated by calf intestinal alkaline phosphatase 
(CIAP/New England Biolab).  Extracts were diluted in 1XCIAP buffer (550uL) and treated with 
CIAP (5uL at 10U/uL) buffer.  Extracts were incubated at 37◦C for 30 minutes and used for 
immunoprecipitation as described in the previous section.   
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 3. RESULTS 
3.1 Expression Analysis of LIM kinase 1 Transgene in Transfected BPH cells 
To confirm that transfected cells were expressing LIMK1 transgene, total RNA extracts 
containing mRNA of BPHLCA, BPHLKD and BPHLK cells were used for RT-PCR. RNA 
concentration was determined by spectrophotometric analysis.  RNA integrity was detected on a 
formaldehyde (3%) agarose gel (1%) which showed intact 18S and 28S ribosomal RNA bands 
(Figure 12).  One microgram of each RNA sample was used for reverse transcriptase PCR 
reaction.  BPH cells expressing transgenes of LIMK1 (BPHLCA, BPHLKD), were amplified using 
upstream PDZ domain primers and downstream Flag specific primers (Figure 12a).  Each sample 
yielded the expected band size of 1.3 kb as a result of LIMK1 transgene amplification.  For 
BHPLK mRNA an upstream kinase domain primer and downstream flag specific primer were 
used which yielded a 1000bp cDNA fragment (Figure 13b).   
Because phosphorylation at T508 activates LIMK1, we wanted to study the effect of 
expression of active LIMK1 or kinase dead LIMK1.  In addition, a cell line expressing only the 
kinase domain of LIMK1 was generated in order to see whether LIM domains are essential for 
the effect of LIMK1.  BPH cells expressinig constitutively active (BPHLCA), kinase dead 
(BPHLKD) and kinase domain only (BPHLK), LIMK1 were generated by stable transfection as 
mentioned before.  BPHLCA was generated by replacing T508, where it is phosphorylated with 
two glutamic acid residues.  This mutation mimics phosphorylation by providing positive charge 
and altering structural conformation (Figure 7).  
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Figure 12 Electrophoresis analysis of total RNA showing intact ribosomal RNA 
 
 
Figure 13 Reverse transcription PCR 
A: Amplicons of BPHLCA and BPHLKD Panel B: Amplicons of BPHLK.  After RT-PCR, cDNAs 
were analyzed by gel electrophoresis. 
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In addition, this mutant of LIMK remains in the open conformation BPHLKD, was 
generated by removal of an aspartic acid residue from the activation loop and replacing it with an 
alanine residue.  Mutation at this position has been shown to inhibit it’s kinase activity. [Rosso et 
al., 2004].   
To identify clones that had the highest expression level of the transgene, western blot 
analysis was done using anti-Flag monoclonal antibody, (Figure 14).  The housekeeping gene 
GAPDH was used as a loading control.  Total protein was extracted from each cell line 
expressing LIM kinase 1 mutants.  These include BPHLCA (constitutively active), BPHLKD 
(kinase dead), BPHLK (kinase domain only) and BPHLV (vector only).  Immunoblot analysis 
showed that all LIM kinase 1 mutants expressed Flag tags (Figure 14).  Protein extracts were 
also analyzed for LIMK1 expression, which showed that BPHL sublines expressing different 
domains of LIMK1, express higher level of LIMK1 relative to untransfected BPH cells, and cells 
transformed with the vector (Figure 15).   
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Figure 14  Flag expression confirms integration of LIMK1 mutants in BPH cell chromosome. 
Lane 1 vector, Lane 2 constitutively active LIMK1, Lane 3 kinase dead mutant, Lane 4 kinase 
domain only mutant.  Fifty microgram of protein was loaded and blot probed with anti Flag 
1:2000 follwed by, anti-mouse-HRP 1:3X104antibodies. 
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Figure 15 Expression analysis of LIMK1.  BPH cells transfected with LIMK1 mutants 
Lane 1:untransfected parental cell line, Lane 2: vector only cell line BPHV, Lane 3: constitutively 
active mutant BPHLCA.  Lane 4:kinase dead mutant, BPHLKD  Lane 5:kinase domain only 
mutant.  Lane 6:PC3-prostate cancer cells which overexpress LIMK.  Fifty microgram of total 
protein loaded in each lane and blot probed with antiLIMK1 antibody at 1:100 dilution. 
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3.2 Catalytically Inactive LIMK1 is Invasive 
Previously, our lab has shown that a reduction in LIMK1 expression results in loss of 
invasiveness in PC3 cells.  Also, ectopic expression of LIMK1 in BPH cells resulted in 
acquisition of highly invasive phenotype.  In this study, we wanted to determine which domains 
of LIMK1 is essential for the invasive property of the protein.  We used a flourormetric invasion 
assay using BPH cells expressing LIMK1 mutants (BPHLCA, BPHLKD, BPHLK) or the vector 
(BPHV). In order to stimulate the EGF signaling pathway, transfected cell lines were treated with 
EGF (10ng/mL) for 24hrs prior to the assay.  EGF signaling pathway stimulates Rho GTPases 
activity in which LIMK1 is a downstream effector kinase.  In addition, we used EGF (100nM) as 
the chemoattractant for invasion assays of BPHL cell lines.  Cells that invaded through the 
matrigel were quantitated by fluorescence reading (Figure 16).  Cells that traversed through the 
matrigel and accumulated in the bottom chamber were counted (Figure 17).  The raw 
fluorescence data showed that the cells expressing BPHLKD had the number of invaded cells 
comparable to that of BPHLCA.  Transfected cell lines expressing BPHLK and BPHV had 
comparable RFU values and were approximately equal to the RFU values of wells without any 
cells.  The cell count data indicated that BPHLCA cells had the highest percentage of invaded 
cells compared to the control cells BPHV.  For the BPHLKD, cell line the percentage of invaded 
cells was similar to that of BPHLCA.  BPHLK cells showed a reduced number of invaded cells.   
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Figure 16 Invitro Invasion assays of EGF treated transfected BPH cells.   
With EGF as an chemoattractant.  Graphical representation of population of cells that penetrated 
matrigel coated membranes.  Values are mean +/- SE of three experiments.  * P=0.820 ** 
P=0.045 and *** P=0.003 when compared to control (BPHV) cells. 
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Figure 17 Percent of invasion of BPH-LIMK1 cell lines 
Relative abundance of the invaded BPH cells BPHK, BPHKD, BPHCA, compared to BPHV cells. 
Values are mean +/- SE of three experiments.  * P=0.009, ** P=0.009, *** P=0.002  when 
compared to control (BPHV) cells.   
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3.3 LIMK 1 Induced Invasion is Mediated by Matrix metalloproteinases 
To determine whether MMPs are involved in LIMK1 mediated invasion, we repeated the above 
assay using GM6001, an inhibitor of matrix metalloproteinase -2 and -9 [Nelson et al., 2000].  
The broad spectrum matrix metalloproteinase inhibitor is GM6001 is a synthetic polypeptide that 
competively inhibits matrix metalloproteinases by occupying the substrate binding sites 
[Boghaert et al., 1994].  Xue et al have shown that GM6001 specifically inhibits MMP-2 and 
MMP-9 in cultured human keratinocytes as observed in in migration assays [Xue et al., 2004].  
For invasion assays, cells were seeded with or without GM6001 (25uM) added to the media and 
the assay was continued as mentioned previously.  Invaded cells were quantitated by 
fluorescence measurement and cell counting as described above.  RFU values showed that there 
was a considerable decrease in invasion of BPHL cell lines expressing constitutively active or 
kinase dead LIMK1 upon treatment with of MMP inhibitor GM6001 (Figure 18).  BPHL cell 
lines expressing constitutively active or kinase dead LIMK1 were equally inhibited. There was 
no change in the invasiveness of BPHLK cells in fluorometric assays upon addition of GM6001.  
However, the number of BPHLK cells that traversed the matrigel membrane were decreased in 
the presence of GM6001 (Figure 19).  The cell count values the showed a greater inhibition of 
invasion in BPHLCA and BPHLK upon treatment with GM6001.  This result supports the 
hypothesis that LIMK1 induced invasion is in part mediated by LIM domains.   
 61
0
500
1000
1500
2000
2500
3000
BPHK BPHKD BPHCA
Cell Lines
R
FU
w/o GM6001
25uM GM6001
 
Figure 18  Inhibition of MMPs decreased invasion of BPH cell lines  
Cell lines expressing different domains of LIMK1 were inhibited.  Graphical representation of 
population of cells that penetrated matrigel coated membranes.  Values are mean +/- SE of three 
experiments.  MMPs inhibitor (GM6001) substantially reduced the ability of BPHLCA and 
BPHLKD to invade matrigel coated membranes.  BPH cells expressing only the kinase domain of 
LIMK1 (BPHLK) were not inhibited by GM6001.  
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Figure 19  MMP inhibitor GM6001 reduced the invasiveness of BPH cells expressing LIMK1  
Transgenes with intact LIM domains.  Graphical representation of population of cells that penetrated matrigel coated 
membranes.  Percentage of cells that traversed through the matrigel membrane and accumulated in the lower chamber.  Values 
are mean +/- SE of three experiments 
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3.3.1 LIMK1 Expression Altered the Concentration of Secreted pro-MMP2 and pro-
MMP9 and increased mRNA Concentration of MMP2 
Subtrate Gel Analysis 
To analyze any alteration in the expression of MMPs in BPH cells expressing LIMK 1 mutants, 
we used gelatinase zymography.  Matrix metalloproteinase -2 and -9 are soluble MMPs which 
are secreted into the extracellular environment.  Therefore, conditioned media from each mutant 
of LIMK1 was harvested and analyzed on 10% SDS gel co-polymrized with denatured collagen 
(gelatin).  Our results showed a graded amount of secreted latent MMP2 (72kD) with the 
maximum, intermediate and least secretion observed in BPHLCA, BPHLKD, and BPHLK cells 
respectively (Figure 20).  BPHLK cells showed the highest level of latent MMP-9 (92kDa), 
(Figure 21).  No secretion of latent MMP9 was observed in the media of BPHLCA, BPHLK D and 
BPHV cells.   
Quantification of mRNA Concentration 
To determine whether LIMK1 expression alters the steady state mRNA concentration of matrix 
metalloprotease -2, quantitative real-time PCR was done using total RNA from the transfected 
BPHLCA and BPHV cells.  The results showed that the mRNA concentration of MMP-2 was~10 
fold higher than BPH cells expressing the vector (BPHLV) (Figure 22).  The concentration of 
MT1-MMP mRNA was unchanged between LIMK1 over expressing samples and BPHV cells. 
No difference in the concentration of MT1-MMP mRNA was noted between BPHLCA and BPHV 
cells.  Therefore the upregulation of MT1-MMP observed in cells expressing constitutively 
active LIMK1 appears to take place at the level of activation level.  The house keeping gene, 
GAPDH was used as a reference.   
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Figure 20 Gelatin zymography of the secreted Matrix Metalloproteinase 2 
(A): Expression of secreted Pro-MMP-2 in transfected BPH cell lines.  BPH cells expressing constitutively active 
LIMK1(BPHLCA) had the highest concentration of Pro-MMP-2.  BPHLKD (kinase dead) and BPHLK cells showed 
also showed comparable levels of secreted Pro-MMP-2 but substantially lower than BPHLCA cells.  BPHV cells 
showed the least amount of secreted.  (B): Densitometric analysis of relative intensity of gelatinoic activity.  Values 
are mean +/- SE of three experiments.  * P=0.028, ** P=0.035*** P=0.010 when compared to control (BPHV) 
cells. 
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Figure 21 Gelatin zymography of secreted Matrix metalloproteinase 9 
(A) BPHL cells expressing only the kinase domain of LIMK1 (BPHLK), had the maximum amount of secreted Pro-
MMP-9.  Transfected BPHLCA, BPHLKD cells showed significantly lower concentrations of secreted Pro-MMP-9. 
BPHV cells had the least amount of secreted pro-MMP-9(B): Densitometric analysis of the relative intensity of 
gelatinoic activity.  Values are mean +/- SE of three experiments.  * P=0.002, ** P=0.018*** P=0.001 when 
compared to control (BPHV) cells. 
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Figure 22 Quantitative Real-time PCR analysis of MMP-2 steady state mRNA 
BPH cells expressing constitutively active LIMK1 had 10 fold increase in MMP-2 mRNA 
concentration relative to vector only control cell line (BPHV).  Normalized average ∆CT values 
for BPHV and BPHLCA were -7 and -3.7, respectively.  Values are means +/- SE of three 
experiments.   
 67
3.4 MT1-MMP Expression positively Correlates with the Concentration of active LIMK1 
Ectopic Expression of Constitutively Active LIMK1 Increased MT1-MMP Expression 
Membrane type I-matrix metalloproteinase is known to activate MMP-2 and possibly MMP-9.  
Furthermore, because it has potent pericelluar ECM degrading activity, MT1-MMP is one of the 
most important regulators of cell migration and invasion.  Upon activation of MT1-MMP 
through cleavage of the pro-peptide by furin like convertases, it is inserted into the plasma 
membrane (Figure 5a).  To analyze whether there is any change in the cell surface expression of 
MT1-MMP, an antibody was used that recognizes the catalytic domain of MT1-MMP, the 
domain exposed to the extra cellular side of the plasma membrane.  Flow cytometric analysis 
indicated that the BPHLCA cells expressed the highest amount of MT1-MMP on the surface 
(Figure 23).  BPHLKD cells expressing catalytically inactive LIMK1 also showed modest 
increase in the cell surface expression of MT1-MMP compared to BPHV control cell.   
Expression of MT1-MMP in BPHLK and BPHV cell lines were comparable but lower than that of 
BPHLCA and BPHLKD.  Because MT1-MMP is targeted to the plasma membrane in it’s active 
form, increased surface expression of MT1-MMP could be considered as increased activity of 
MT1-MMP.  Therefore, it could be inferred that increased expression of active LIMK1 increased 
the activity of MT1-MMP in BPHLCA cells.  For densitometric analysis, the cells that were 
emitting fluorescence were gated out from the nonfluorescent cells and calculated as the 
percentage of the control (BPHV) cells (Figure 24).   
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Figure 23  Flow cytometric analysis of MMP-14 cell surface expression in transfected BPH cell lines.   
Two parameter histograms with fluorescence intensities in the X axis and number of cells in the Y axis.  A total of 
10.000 cells were counted.  Black histogram represents unstained cells, red histrogram represents population of 
fluorescent cells within each sample.  Data shows a noticeable shift in the red histogram of BPHLCA cells 
representing high number of cells with fluorescence.  The red histogram of BPHLKD cells also showed a shift 
towards the right representing increased number of cells with fluorescence compared to that of BPHV cells.  Red 
histogram of BPHV cells showed minimum shift indicating minimal number of fluorescent cells.  A modest shift in 
the red histogram was noted in BPHLK cells representing fluorescent cells with some degree of MT1-MMP 
expression.   
BPHV BPHK
BPHKD BPHCA
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Figure 24 Relative Expression of MT1-MMP in BPH cells expressing different domains of 
LIMK1.   
Quantitative analysis of flourescent cells after elimination of cell debris and non-flourescent 
cells.  Data represents the average +/- SE of three independent experiments.  * P=0.136, ** 
P=0.109 and *** P=0.05.   
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Expression of LIMK1 Transgenes Increased Concentration of MT1-MMP 
Total protein were extracted from LIMK1 expressing cell lines and analyzed by western blots 
using anti-MT1-MMP antibody.  .  The results showed a considerable increase in MT1-MMP 
latent and active protein levels in BPHLCA cell line compared to the vector only control cell line 
BPHV (Figure 25).  As a positive control PC3 extracts were used as they express high levels of 
MT1-MMP [Daja et al., 2003].  The level of MT1-MMP observed in BPHLKD was comparable 
to but less than that of BPHLCA.  BPHLK cells showed the least amount of MT1-MMP.  The 
vector only cell line (BPHV) did not express any MT1-MMP.  This data also substantiates a 
positive correlation between LIMK1 and MT1-MMP protein levels.  
MT1-MMP Co-localizes with LIMK1 in the Perinuclear Region 
To determine the intracellular localization of MT1-MMP, dual label immunoflourescence using 
antibodies of MT1-MMP and Flag was performed.  A distinct difference in cell morphology was 
noted in cells expressing active LIMK1, kinase dead LIMK1 and only the kinase domain.  
Lamellipodia and filopodia extensions were observed in constitutively active (BPHLCA) cells 
(Figure 26).  Cellular morphology and localization pattern of MT1-MMP in BPH cells 
expressing LIMK1 with intact LIM domains (BPHLCA and BPHLKDcells) were comparable, 
although more ruffling membranes were noted in BPHLCA cells.  In BPHLK cells, microspikes 
were observed.  Also, BPHLK cells were clustered together and showed a more adherent 
phenotype.  Higher concentration of MT1-MMP was also observed in BPHLCA cells.  In 
addition, co-localization of MT1-MMP and constitutively active LIMK1 to the perinuclear 
region was most evident in BPHLCA cells.  Flag staining observed in was BPHV was essentially 
non-existant compared to BPHL sublines. 
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Figure 25 Expression of Pro-MT1-MMP and active MT1-MMP in BPH-LIMK cell lines 
Western blot analysis of MT1-MMP in BPH crude extracts of expressing LIMK1 mutants.  
Metastatic prostate cancer cells (PC3) that express high levels of LIMK1, also showed 
expression of latent and active MT1-MMP.   
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Figure 26 MT1-MMP localization studies of BPH cells expressing mutant LIMK1 
In BPHLK cells diffused cytoplasmic and nuclear localization of LIMK1 (green) and appearance 
of microspikes (arrow) could be seen.  Localization of MT1-MMP in these cells was mainly to 
the perinuclear region.  In BPHLKD cells, LIMK1 was localized to the nuclei and to the plasma 
membrane (arrow).  BPHLKD merged image shows that MT1-MMP is distributed throughout the 
cytoplasm and co-localized with LIMK1 (arrow).  In BPHLCA cells, increased concentration of 
constitutively active LIMK1 to the plasma membrane was evident. Appeaance of lamellipodia 
also could be seen in these cells.  BPHLCA cells, showed the most intense staining of MT1-MMP 
and accumulation of LIMK1 to ruffling membranes (merged image, arrows). 
MT1-MMP localization was observed in the perinuclear to cytoplasmic region in BPHLCA and 
BPHLKD cell lines.  However, in BHPLKD cells, MT1-MMP staining was more concentrated to 
the perinuclear region.  Further, the results showed modest co-loclization between constitutively 
active LIMK1 and MT1-MMP in the membrane ruffles. 
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3.5 Phospho-LIMK1/2 Associates with γ-Tubulin  
Role of LIMK1 in Mitosis 
Disruption of highly orchestrated processes like mitosis and cytokenesis causes chromosomal 
instability and subsequent tumor progression [Ohbayashi et al., 2007].  In addition, LIMK1 has 
been shown to coordinate microtubule instability through co-localization with microtubules and 
complex formation via PDZ domain [Gorovoy et al., 2005].  Induction of microtubule 
destabilization by treatment with nocodazole resulted in decreased association with LIMK1.  
Because centrosomes are critically involved in mitotic spindle formation we studied the 
distribution of phospho-LIMK1/2 in the mitotic cells.   
Co-localization studies of p-LIMK1/2 and γ-tubulin 
Immunoflourescence analysis of metastatic (MDA-MB-231) and normal (HMEC) breast 
epithelial cells (HMEC) revealed that phospho-LIMK1 and γ-tubulin co-localize to the 
centrosome during prophase, metaphase and anaphase (Figure 8).  This pattern of localization 
was also observed in the invasive prostate cancer cell line DU145 (data not shown). This co-
localization diminishes at the onset of telophase. Visualization of phospho-LIMK1 and γ-tubulin 
localization was accomplished using a monoclonal α-gamma tubulin and polyclonal α-phospho-
LIMK1 antibodies.  To determine optimal dilution of phospho-LIMK1/2 to be used in western 
blot analysis, both antibodies were titrated using crude nuclear extracts of LNCap and BPH 
whole cell extracts (Figure 27).  Western blot analysis showed that 1:50 was the optimal dilution 
to use for 50ug of nuclear extracts. Immunoprecipitation with γ-tubulin antibody pulled down 
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Figure 27  Titration of phospho-LIMK1/2 antibody in BPHL cells 
(A) Titration of p-LIMK1.  (B) Titration of and p-LIMK2.  GAPDH was used as a loading 
control.  Fifty microgram of crude BPH extracts were used. 
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Figure 28 Biochemical interactions between phospho-LIMK1 and γ-tubulin 
Panel (A) Upper and middle panel: Western blot analysis of p-LIMK1and p-LIMK1 in crude 
nuclear extracts and immunoprecipitates with γ-tubulin antibody using MDA-MB-231 cells.  
Lower panel: Treament of MDA-MB-231 cells with CIAP or immunoprecipiton with non-
specific antibody followed by western blot analysis with anti-phospho-LIMK1.  Panel (B): 
Western blots of p-LIMK1, γ-tubulin and Flag-tagged LIMK1 in crude and γ-tubulin 
immunoprecipitates of nuclear extracts of BPHLFLAG cells.  Panel (C) Western blots of p-LIMK1 
and γ-tubulin in Flag immunoprecipitates of nuclear extracts of BPHFLAG cells.  
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phospho-LIMK1. This interaction between γ-tubulin and p-LIMK1/2 was shown to exist in BPH 
cells over expressing LIMK1 and MDA-MB-231 breast cancer cells (Figure 28a/b). To confirm 
that γ-tubulin specifically associated with phospho-LIMK1, nuclear extracts were treated with 
calf intestinal alkaline phosphatase (CIAP).  Treatment with CIAP removes phosphate groups 
from all phosphorylated protein.  Therefore CIAP treated nuclear extracts did not precipitate with 
γ-tubulin as indicated by post immunoprecipitation immunoblot analysis (Figure 28a).  This 
confirms that γ-tubulin associates with LIMK1 only in phosphorylated form.  
Immunoprecipitation with an unrelated antibody showed that γ-tubulin was specifically 
associating with p-LIMK1 (Figure 28a). In addition, immunoprecipitation with Flag antibody 
also pulled down γ-tubulin and phospho-LIMK1 (Figure 8c).  Therefore recombinant LIMK1 
expressed in BPH cells is also associating with γ-tubulin.  
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4. DISCUSSION 
4.1 LIM kinase 1 and Matrix metalloproteases 
LIM kinase 1 has been identified as a required component for the invasion of prostate 
epithelial cells [Davila et al., 2003].  To determine the structure-function relationship of LIM 
kinase 1 mediated invasion, mutant constructs were designed.  BPH cells stably over expressing 
a kinase domain only mutant of LIM kinase 1 (BPHLK) showed decreased invasiveness when 
compared to kinase dead mutant (BPHLKD) and constitutively active mutant (BPHLCA) of LIM 
kinase 1.  The percent invasion for BPHLCA and BPHLKD cell lines were comparable.  The 
kinase domain only of LIMK1 mutant did not promote invasion of BPH cells.  Phosphorylation 
of LIMK1 at T508 allows dissociation of the LIM domains from the kinase domain. When LIM 
kinase 1 becomes phosphorylated, it ‘s conformation changes from closed to open, thereby 
making the LIM domains accessible (Figure 7).  Therefore it is reasonable to assume that the 
highly invasive phenotype seen in BPHLCA cell line may be due to increased protein:protein 
interactions involving the LIM and/or the PDZ domain., kinase activity, or both.  In fact, current 
studies showed a correlation between the protein:protein interaction of LIM domain containing 
proteins PELP1 and FHL2 with prostate cancer progression [Nair et al., 2007].  This data suggest 
that the LIM domains of LIM kinase 1 may be necessary for the invasiveness of cancerous 
prostate. This result further implies that LIM kinase 1 is able to induce invasion independent of 
it’s kinase activity.  While there is conflicting evidence as to the role of LIM kinase 1 in 
promotion or inhibition of tumor cell invasion [Wang et al., 2006], the data presented here 
supports a pro-invasive role for LIM kinase 1 in the absence of it’s kinase activity in prostate 
epithelial cells.  In addition, little is known about the mechanism by which LIM kinase 1 exerts 
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it’s effect.  However, research from other laboratories showed that the regulation of cofilin by 
LIMK1 is central to LIM kinase 1 mediated invasiveness [Zebda et al., 2000].  The reason for 
these opposite findings is not known.  However, based on this study, one can speculate that there 
may be interacting proteins associated with the LIM and PDZ domains, which are in part 
responsible for invasion, and that the activity of LIM kinase 1 contributes to invasion but is not 
necessary for invasion.  
To understand the mechanism underlying LIM kinase 1 mediated invasion we monitored 
the effect of inhibition of matrix metalloprotease 2/9 on the ability of BPH-LIMK1 cell lines to 
invade matrigel coated membrane in vitro.  Because MMPs have been shown to be involved in 
prostate cancer cell invasion [Wilson et al., 2004], we hypothesized that they may also be 
involved in LIM kinase 1 mediated prostate cancer cell invasion.  Inhibition of MMPs resulted in 
considerable decrease in invasion of BPH cells expressing kinase dead or active LIMK1 through 
matrigel coated membranes.  Matrix metalloprotease inhibition had the greatest effect on BPH 
cells expressing active LIMK1.  There is substantial evidence implicating matrix 
metalloprotease-2 and matrix metalloprotease-9 as key enzymes in prostate cancer cell invasion, 
[Vayalil and Katiyar, 2004], [Vijayababu et al., 2006], [Sehgal and Thompson, 1999], [Hong et 
al., 2006].  In agreement with published reports, we found that MMP-2 and MMP-9 are involved 
in the invasion of prostate epithelial cells.  However, to our knowledge, our study provides novel 
data that links the expression of LIM kinase 1 activity to the expression of matrix 
metalloproteases.  Gelatinase zymography analysis showed that the BPHCA cell line produced the 
highest concentration of secreted latent MMP-2.  Conversely, the highest concentration of MMP-
9 was seen in BPHK cell line.  Comparable concentration of secreted latent MMP-2 was observed 
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in BPHKD.  In comparison, BPH cells stably expressing kinase dead (BPHK) or the vector 
(BPHV) had minimal levels of latent MMP-2.    These data further confirms that MMPs have an 
integral role to play in prostate cancer cell invasion. It also showed a positive correlation 
between LIM kinase 1 induced expression and the secretion of soluble MMP-2.  It could be 
speculated that LIM kinase 1 may have a role in either the expression, regulation, or activation of 
MMP-2  
Quantitative RT-PCR data showed that LIMK1 is involved in alteration of the mRNA 
levels of MMP-2.  We used BPH cells expressing constitutively active LIMK1 or vector only.  
The results show a 10 fold increase in the steady state mRNA levels of MMP-2 in BPH cells 
over expressing LIM kinase 1 relative to the vector control. GAPDH was used as a reference 
gene.  These results showed that LIM kinase 1expression increased the steady state level of  
MMP-2 mRNA compared to control BPH cells.  Our data on MMP-2 and MMP-9 expression in 
prostate cancer cells provides further evidence to support current knowledge [Aalinkeel et al., 
2004; Pratap et al., 2005; Singh et al., 2004] and also extends the understanding by linking 
MMP-2 and MMP-9 expression to LIM kinase 1.  Our data supports our hypothesis that LIM 
kinase 1 induced invasion is mediated by MMPs . And further, this correlation is seen at the level 
of mRNA concentration and protein expression.   
Membrane-type I matrix metalloprotease is vital for initiation of ECM degradation 
[Udayakumar et al., 2004], [Bair et al., 2005], [Golubkov et al., 2005].  MT1-MMP (also called 
MMP-14) not only directs the degradation of cell surface ECM, but also activates MMP-2, 
another potent ECM degrading family member [Dong et al., 2005], [Cardillo et al., 2006].  Using 
flow cytometric analysis we were able to quantitate the level of “processed” MMP-14 at the 
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plasma membrane in benign prostate epithelial cells.  In addition, our results showed that upon 
treatment with EGF there was a considerable increase in MT1-MMP signal intensity compared 
to samples not treated with EGF (data not shown).  This result complies with current research 
that identifies EGF signaling as an upregulated pathway in prostate cancer [Mimeault et al., 
2007b], [Angelucci et al., 2006].  It is logical to assume that EGF signaling increases the level of 
active endogenous LIM kinase 1 mediated by Rac 1 while simultaneously inducing MT1-MMP 
expression [Kheradmand et al., 2002], [Van Meter et al., 2004] [Yeh et al., 2006].  In addition, 
EGFR signaling increases the activation of both LIM kinase 1 and MT1-MMP in prostate cancer 
cells.  In this study, we show increased expression of MT1-MMP on the cell surface in BPH cells 
stably expressing constitutively active LIM kinase 1.  Cell lines expressing, kinase dead and 
kinase domain mutants of LIM kinase 1, showed comparable levels of MT1-MMP expression 
relative to the control.  Since MT1-MMP is only inserted into the plasma membrane after 
cleavage and activation by furin convertases , [Hernandez-Barrantes et al., 2000] we can argue 
that over expression of LIM kinase 1 correlates with increased expression and increased activity 
of MT1-MMP. 
Immunoflourescence analysis revealed that LIM kinase 1 and MT1-MMP co localize to 
the perinuclear to cytoplasmic region in BPH.  Current research shows that MT1-MMP targeting 
to the plasma membrane is necessary for migrating cells to become invasive [Strongin, 2006].  
Cell lines expressing constitutively active and kinase dead mutants showed distinct formation of 
lammellipodia and membrane ruffles upon treatment with EGF.  However a dramatic effect was 
seen in cells expressing constitutively active LIM kinase 1.  In addition, co-localization of LIM 
kinase 1 and MT1-MMP in the membrane ruffles was observed in BPHLCA.  This data suggest 
 83
that LIM kinase 1 and MT1-MMP are both involved in the formation of structures relevant to 
tumor cell motility and that these enzymes may be functionally or mechanistically related.  We 
can also infer that sub cellular localization of MT1-MMP is in part dependant on LIM kinase 1 
expression and/or activity.  BPH cells expressing only the kinase domain showed substantial 
formation of micro spikes; which are consistent with Rho signaling effects [Aznar et al., 2004].  
No specific localization was seen in the control cell line expressing the vector.  Our localization 
studies focused on LIM kinase 1 and MT1-MMP support the hypothesis that LIM kinase 1 
induced invasion is mediated by matrix metalloproteases.  Moreover, we provide further 
evidence in support of the current knowledge that MT1-MMP is involved in the migration of 
cancer cells [Lehti et al., 2000].  MT1-MMP and LIM kinase 1 may act synergistically to each 
other in the process of tumor cell migration and invasion. 
The work presented here is important because it expounds on the key molecules that are 
involved in prostate cancer cell progression to invasiveness.  Matrix-metalloproteinase’s are 
extra cellular matrix degrading enzymes with clear and direct links to malignancy [Nelson et al., 
2000].  Independantly, LIM kinase 1 and matrix metalloproteases expressions have been strongly 
implicated with increasing malignancy  Our study shows that there may be cross-talk between 
these two proteins in promotion of invasion. This study also provides evidence that LIM kinase 1 
mediated invasion can occur independent of it’s kinase activity.  The data also indicate that in the 
absence of the LIM domains, BPH cells showed considerably decreased invasiveness.  This 
strongly indicates the LIM domains are critical to the invasiveness of LIM kinase 1.  To confirm 
this speculation, a mutant of LIM kinase 1 that is both kinase dead and constitutively open can be 
studied.  Taken together these results elucidate the mechanisms involved in prostate cancer cell 
 84
invasion by linking LIM kinase 1 to MMPs.  Both of which are independently known to be 
involved in tumor cell migration and invasion.  Identification of molecular drug targets for tumor 
cell invasion relies on the elucidation of the complex mechanism of metastasis.  This data 
provides evidence that LIM kinase 1 could be a target for anti-metastatic drug that could possibly 
effect the matrix metalloproteinase’s.  In addition, Meng et al have shown that knockout LIM 
kinase 1 mice display only minor abnormalities; hence LIM kinase 1 represents an ideal target 
for drug design [2002].   
4.2 LIM KINASE 1 and γ-Tubulin 
LIM kinase 1 is well established as a potent regulator of the actin cytoskeleton through 
it’s interaction with cofilin [Zebda et al., 2000].  Previous studies have revealed that LIM kinase 
1 has a role in the stabilization of microtubules [Gorovoy et al., 2005].  Cell motility, migration 
and division are processes that rely on the coordination between microtubules and actin 
cytoskeleton [Rodriguez et al., 2003].  Sumi et al  showed that LIM kinase 1 activation and 
subsequent targeting to the spindle pole is regulated by cell cycle progression in HeLa cells.  The 
data presented here further supports these findings.  During interphase, epiflourescence imaging 
showed that phospho-LIM kinase 1 is not co-localized with γ-tubulin.  However upon activation 
and the onset of mitosis a distinct localization is seen between γ-tubulin and phospho-LIM 
kinase1 to the spindle poles.  This p-LIM kinase 1/γ-tubulin association was abolished during 
telophase where p-LIM kinase 1 concentrated to the cleavage furrow.  This pattern of 
localization between p-LIM kinase 1 and γ-tubulin was observed in the slightly metastatic 
prostate cancer cell line DU-145, in the highly invasive breast cancer cell line MDA-MB-231 
and in normal benign breast cancer cells, HUMEC.  This indicates that this interaction is not 
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cancer cell specific and that it may represent a novel role for LIM kinase 1 in the regulation of 
cell division.  We propose that inactive LIM kinase 1 is bound to microtubules during interphase 
and when it becomes phosphorylated it is released from microtubule and targeted to the 
centrosome where it associates with γ-tubulin.  Other studies showed a similar cell cycle 
dependant activation of Ajuba (a LIM containing protein) and subsequent co-localization with γ-
tubulin to the centrosome [Abe et al., 2006]. 
Immunoprecipitation reactions confirmed that p-LIM kinase 1 associates with γ-tubulin 
Nuclear extracts of BPH and MDA-MB-231 immunoprecipitated with γ-tubulin and blotted with 
p-LIM kinase 1 gave a positive result.  Western blot analysis of nuclear extracts 
immunoprecipitated with a un-related antibody could not be detected by probing with anti-
phospho-LIMK1.  Similarly, nuclear extracts immunoprecipitated with non-specific antibody 
and immuno blotted with p-LIM kinase 1 antibody did not yield a signal.  This result confirms 
that p-LIM kinase 1 is specifically associating with γ-tubulin.  To prove that p-LIM kinase 1 and 
not LIM kinase 1 is associating with γ-tubulin, nuclear extracts were treated with calf intestinal 
alkaline phosphatase (CIAP) to remove phosphate group from all proteins.  CIAP treated extracts 
were processed and showed no band after immunoblotting with p-LIM kinase 1.  It is important 
to mention that p-LIM kinase 2 also associated with γ-tubulin.  This result suggest that p-LIM 
kinase 1 may have an indirect role in mitotic spindle assembly through its interaction with γ-
tubulin at the centrosome during prometaphase to anaphase.  Therefore over expression of 
LIMK1 in cancer cells may promote chromosomal instability and spindle defects. 
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